Jordi Rodon Ahnert, MD, PhD

Peer-Reviewed Articles

1. Ngoi, NY, Silverman, IM, Johnson, A, Meng, C, Schonhoft, JD, Zimmermann, M, Ulanet, D, Kim, H, Torrado, C, Salguero, C, Brown, C, Rodon Ahnert, J, Rimkunas, V, Koehler, M, Yap, TA. Exceptional response to the ATR inhibitor, camonsertib, in a patient with ALT+ metastatic melanoma. npj Precision Oncology 9(1), 2025. e-Pub 2025. PMID: 40624157.
2. Ouyang, Q, Rodon Ahnert, J, Liang, Y, Wu, X, Li, Q, Song, L, Yan, M, Tong, Z, Liu, YP, Wainberg, ZA, Wang, Y, Geng, CZ, Ulahannan, SV, Yu, GH, Sharma, MR, Wang, X, Wang, JS, Spira, AI, Zhao, W, Sanborn, RE, Cheng, Y, Wang, X, Liu, G, Li, Y, Ge, J, Chartash, E, Akala, OO, Yin, YM. Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies. Journal of Hematology and Oncology 18(1), 2025. e-Pub 2025. PMID: 40481574.
3. Lin, SH, Subbiah, V, Cohen, E, Li, Z, Lu, YJ, Son, YL, Lyu, Y, Gao, H, Jayachandran, G, Neri, S, Sharma, A, Fang, PQ, Karp, DD, Hong, DS, Rodon Ahnert, J, Yu, H, Peng, J, Lloyd, GK, Tonra, JR, Reuben, JM, Huang, L, Fu, S. Plinabulin following radiation enhances dendritic cell maturation and checkpoint inhibitor retreatment of relapsed/refractory cancers. Med 6(10), 2025. e-Pub 2025. PMID: 40580957.
4. Nelson, BE, Janku, F, Fu, S, Ileana Dumbrava, EE, Hong, DS, Karp, DD, Naing, A, Rodon Ahnert, J, Tsimberidou, AM, Murthy, R, Sheth, RA, Amaria, RN, Conley, AP, Damodaran, S, Raghav, KS, Carapanceanu, N, Singh, MP, Carapanceanu, V, Pezeshki, A, Leontovich, A, Kreider, B, Tung, D, Varterasian, M, Khazaie, K, Piha-Paul, SA. Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. Clinical Cancer Research 31(18):3864-3875, 2025. e-Pub 2025. PMID: 40643985.
5. Chen MK, Yamaguchi H, Gao Y, Xia W, Chang JT, Hsiao YC, Shegute TW, Lin ZS, Wu CS, Wang YH, Litton JK, Ding Q, Wei Y, Chu YY, Meric-Bernstam F, Piwnica-Worms H, Arun B, Rodon Ahnert J, Liu J, Yao J, Chang WC, Wang HL, Tapia C, Albarracin CT, Keyomarsi K, Wang SC, Wang YN, Hortobagyi GN, Lin C, Yang L, Yu D, Hung MC. FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models. J Clin Invest 135(14), 2025. e-Pub 2025. PMID: 40460005.
6. Zhao, S, Cheng, Y, Wang, Q, Li, X, Liao, J, Rodon Ahnert, J, Meng, X, Luo, Y, Chen, Z, Wang, W, Yi, T, Li, Y, Yin, YM, Xu, H, Yu, GH, Mi, YJ, Fan, Y, Wainberg, ZA, Wang, X, Su, C, Yu, Q, Lai, SZ, Sun, L, Zhuang, W, Wang, X, Yang, J, Li, Y, Ge, J, Li, J, Zhang, L, Fang, W. Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations. Nature medicine 31(6):1976-1986, 2025. e-Pub 2025. PMID: 40210967.
7. Rodon Ahnert, J, Rothe, M, Mangat, PK, Garrett-Mayer, E, Cannon, TL, Hobbs, EA, Kalemkerian, GP, Hinshaw, DC, Gregory, A, Grantham, GN, Halabi, S, Schilsky, RL. Afatinib in patients with solid tumors with neuregulin 1 (NRG1) fusions. ESMO Open 10(5), 2025. e-Pub 2025. PMID: 40215596.
8. Lopez, J, Milhem, M, Butler, M, Thistlethwaite, FC, Van Tine, BA, D'Angelo, S, Johnson, M, Sato, T, Arkenau, HT, Edukulla, R, Wustner, J, Marshall, S, Rodon Ahnert, J. Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies. Cell Reports Medicine 6(4), 2025. e-Pub 2025. PMID: 40054461.
9. Gouda, MA, Gonugunta, A, Ileana Dumbrava, EE, Yap, TA, Rodon Ahnert, J, Piha-Paul, SA, Pohlmann, PR, Damodaran, S, Murthy, RK, Valero, V, Mouabbi, JA, Tripathy, D, Sahin, AA, Chen, H, Meric-Bernstam, F. Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer. Clinical Cancer Research 31(7):1268-1274, 2025. e-Pub 2025. PMID: 39841861.
10. Bosch-Barrera, J, Estévez-García, P, Martin-Martorell, P, Sabatier, R, Nadal, E, Sais, E, Gascon, P, Oaknin, A, Rodon Ahnert, J, Lizcano, JM, Muñoz-Guardiola, P, Fierro-Durán, G, Pedrós-Gámez, O, Pérez-Montoyo, H, Yeste-Velasco, M, Cortal, M, Pérez-Campos, A, Alfón, J, Domènech, C, Moran, T. ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer. Lung Cancer 201, 2025. e-Pub 2025. PMID: 39983444.
11. Ahmed, J, Knisely, A, Torrado, C, Stephen, B, Yang, Y, Song, J, Alshawa, A, Zarifa, A, Jhingran, A, Koay, EJ, Morris, VK, Javle, M, Wolff, RA, Meric-Bernstam, F, Pant, S, Rodon Ahnert, J, Naing, A. A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies. Oncologist 30(3), 2025. e-Pub 2025. PMID: 40139261.
12. Schram, AM, Goto, K, Kim, DW, Macarulla, T, Hollebecque, A, O'Reilly, EM, Ignatius Ou, SH, Rodon Ahnert, J, Rha, SY, Nishino, K, Duruisseaux, M, Park, JO, Neuzillet, C, Liu, SV, Weinberg, BA, Cleary, JM, Calvo, E, Umemoto, K, Nagasaka, M, Springfeld, C, Bekaii-Saab, T, O'Kane, GM, Opdam, FL, Reiss, KA, Joe, AK, Wasserman, E, Stalbovskaya, V, Ford, J, Adeyemi, S, Jain, L, Jauhari, S, Drilon, A. Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer. New England Journal of Medicine 392(6):566-576, 2025. e-Pub 2025. PMID: 39908431.
13. Gouda, MA, Wei, Z, Rodon Ahnert, J, Davies, MA, Janku, F, Gray, R, Wang, V, McShane, LM, Rubinstein, L, Patton, DR, Williams, PM, Hamilton, SR, Liu, R, Bota, DA, Swiecicki, PL, Buchschacher, G, Tricoli, JV, Conley, BA, Arteaga, CL, Harris, LN, O'Dwyer, PJ, Chen, A, Flaherty, KT. Phase II Study of Copanlisib in Patients With PTEN Loss. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 39913886.
14. Piha-Paul, SA, Tseng, C, Tran, HT, Naing, A, Dumbrava, EE, Karp, DD, Rodon Ahnert, J, Yap, TA, Raghav, KS, Damodaran, S, Le, X, Soliman, PT, Lim, J, Meric-Bernstam, F. Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations. ESMO Open 10(2), 2025. e-Pub 2025. PMID: 39908697.
15. Alhalabi, O, Gouda, MA, Milton, D, Momin, HA, Yilmaz, B, Stephen, B, Ejezie, CL, Moyers, JT, Gurses, S, How, JA, Fu, S, Rodon Ahnert, J, Hong, DS, Piha-Paul, SA, Subbiah, V, Elena Dumbrava, E, Karp, DD, Janku, F, Meric-Bernstam, F, Tannir, NM, Naing, A. A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma. Cancer medicine 14(4), 2025. e-Pub 2025. PMID: 39945382.
16. DiPeri, TP, Evans, KW, Scott, S, Zheng, X, Varadarajan, K, Kwong, L, Kahle, M, Cao, HS, Tzeng, CW, Vu, T, Kim, S, Su, F, Raso, G, Rizvi, YQ, Zhao, M, Wang, H, Lee, SS, Yap, TA, Rodon Ahnert, J, Javle, M, Meric-Bernstam, F. Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer. Clinical Cancer Research 31(2):387-402, 2025. e-Pub 2025. PMID: 39513959.
17. Belmontes, B, Slemmons, KK, Su, C, Liu, S, Policheni, AN, Moriguchi, J, Tan, H, Xie, F, Aiello, DA, Yang, Y, Lazaro, R, Aeffner, F, Rees, MG, Ronan, MM, Roth, JA, Vestergaard, M, Cowland, S, Andersson, J, Sarvary, I, Chen, Q, Sharma, P, Lopez, P, Tamayo, N, Pettus, LH, Ghimire-Rijal, S, Mukund, S, Allen, JR, DeVoss, JJ, Coxon, A, Rodon Ahnert, J, Ghiringhelli, F, Penel, N, Prenen, H, Glad, S, Chuang, CH, Keyvanjah, K, Townsley, DM, Butler, JR, Bourbeau, MP, Caenepeel, S, Hughes, PE. AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers. Cancer discovery 15(1):139-161, 2025. e-Pub 2025. PMID: 39282709.
18. Xavier, CB, Andersen, C, Lim, J, Slade, JH, Bean, S, Kang, L, Le, H, Tsimberidou, AM, Naing, A, Hong, DS, Ileana Dumbrava, EE, Rodon Ahnert, J, Pohlmann, PR, Piha-Paul, SA, Champiat, S, Yap, TA, Tang, T, Meric-Bernstam, F, Fu, S. Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials. Cancer Research Communications 5(9):1631-1641, 2025. e-Pub 2025. PMID: 40862547.
19. Ogoti, BM, Riitho, V, Rodon Ahnert, J, Mutono, N, Tesch, J, Oyugi, J, Mureithi, M, Corman, VM, Drosten, C, Wildemann, J, Thumbi, SM, Müller, MA. On-site detection of MERS-CoV infections in a camel slaughterhouse in Kenya using a commercial rapid antigen test. Frontiers in Veterinary Science 12, 2025. e-Pub 2025. PMID: 41030676.
20. Nardo, M, Gouda, MA, Reilley, MJ, Biter, A, Lim, J, Bean, S, Nguyen, LM, Bhosale, PR, Ager, CR, Couillault, CA, Piha-Paul, SA, Fu, S, Tsimberidou, AM, Yap, TA, Naing, A, Rodon Ahnert, J, Subbiah, V, Karp, DD, Curran, M, Hong, DS. Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors. Journal of Immunotherapy and Precision Oncology 8(2):89-98, 2025. e-Pub 2025. PMID: 39959251.
21. Rodon Ahnert, J, Prenen, H, Sacher, A, Villalona-Calero, M, Penel, N, El Helali, A, Rottey, S, Yamamoto, N, Ghiringhelli, F, Goebeler, ME, Doi, T, Postel-Vinay, S, Lin, CC, Liu, C, Chuang, CH, Keyvanjah, K, Eggert, T, O'Neil, BH. First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors. Annals of Oncology 35(12):1138-1147, 2024. e-Pub 2024. PMID: 39293516.
22. Rodon Ahnert, J, Demanse, D, Rugo, H, Burris, H, Simó, R, Farooki, A, Wellons, M, André, F, Hu, H, Vuina, D, Quadt, C, Juric, D. A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer. Breast Cancer Research 26(1), 2024. e-Pub 2024. PMID: 38439079.
23. Westphalen, CB, Martins-Branco, D, Beal, JR, Cardone, C, Coleman, N, Schram, AM, Halabi, S, Michiels, S, Yap, C, Andre, F, Bibeau, F, Curigliano, G, Garralda, E, Kummar, S, Kurzrock, R, Limaye, SA, Loges, S, Marabelle, A, Marchiò, C, Mateo, J, Rodon Ahnert, J, Španić, T, Pentheroudakis, G, Subbiah, V. The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S). Annals of Oncology 35(11):936-953, 2024. e-Pub 2024. PMID: 39187421.
24. Chang, JY, Xu, X, Shroff, G, Comeaux, NI, Li, W, Rodon Ahnert, J, Karp, DD, Ileana Dumbrava, EE, Verma, V, Chen, A, Welsh, J, Hong, DS. Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies. Journal for immunotherapy of cancer 12(10), 2024. e-Pub 2024. PMID: 39384194.
25. Chen, S, Hou, J, Jaffery, R, Guerrero, AM, Fu, R, Shi, L, Zheng, N, Bohat, R, Egan, NA, Yu, C, Sharif, S, Lu, Y, He, W, Wang, S, Gjuka, D, Stone, E, Shah, P, Rodon Ahnert, J, Chen, T, Liu, X, Bedford, MT, Xu, H, Peng, W. MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors. Journal for immunotherapy of cancer 12(9), 2024. e-Pub 2024. PMID: 39313308.
26. Majd, NK, Vo, H, Moran, CA, Weathers, S, Song, IW, Williford, G, Rodon Ahnert, J, Fu, S, Tsimberidou, AM. Metastatic extraneural glioblastoma diagnosed with molecular testing. Oncologist 29(9):811-816, 2024. e-Pub 2024. PMID: 38837109.
27. Piha-Paul SA, Tseng C, Leung CH, Yuan Y, Karp DD, Subbiah V, Hong D, Fu S, Naing A, Rodon J, Javle M, Ajani JA, Raghav KP, Somaiah N, Mills GB, Tsimberidou AM, Zheng X, Chen K, Meric-Bernstam F. Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. NPJ Precis Oncol 8(1):166, 2024. e-Pub 2024. PMID: 39085400.
28. Tang, C, Hartley, G, Couillault, CA, Yuan, Y, Lin, Y, Nicholas, C, Srinivasamani, A, Dai, J, Ileana Dumbrava, EE, Fu, S, Karp, DD, Naing, A, Piha-Paul, SA, Rodon Ahnert, J, Pant, S, Subbiah, V, Yap, T, Tsimberidou, AM, Guerrero, PA, Dhebat, S, Proia, T, Curran, M, Hong, DS. Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer. BMJ Oncology 3(1), 2024. e-Pub 2024. PMID: 39886125.
29. Leary A, Estévez-García P, Sabatier R, Ray-Coquard I, Romeo M, Barretina-Ginesta P, Gil-Martin M, Garralda E, Bosch-Barrera J, Morán T, Martin-Martorell P, Nadal E, Gascón P, Rodon J, Lizcano JM, Muñoz-Guardiola P, Fierro-Durán G, Pedrós-Gámez O, Pérez-Montoyo H, Yeste-Velasco M, Cortal M, Pérez-Campos A, Alfon J, Domenech C, Pérez-Fidalgo A, Oaknin A. Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer : Alexandra Leary. BMC Cancer 24(1):911, 2024. e-Pub 2024. PMID: 39075404.
30. Leary A, Estévez-García P, Sabatier R, Ray-Coquard I, Romeo M, Barretina-Ginesta P, Gil-Martin M, Garralda E, Bosch-Barrera J, Morán T, Martin-Martorell P, Nadal E, Gascón P, Rodon J, Lizcano JM, Muñoz-Guardiola P, Fierro-Durán G, Pedrós-Gámez O, Pérez-Montoyo H, Yeste-Velasco M, Cortal M, Pérez-Campos A, Alfon J, Domenech C, Pérez-Fidalgo A, Oaknin A. ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer. BMC Cancer 24(1):876, 2024. e-Pub 2024. PMID: 39039449.
31. Maldonado E, Rathmell WK, Shapiro GI, Takebe N, Rodon J, Mahalingam D, Trikalinos NA, Kalebasty AR, Parikh M, Boerner SA, Balido C, Krings G, Burns TF, Bergsland EK, Munster PN, Ashworth A, LoRusso P, Aggarwal RR. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer Res Commun 4(7):1793-1801, 2024. e-Pub 2024. PMID: 38920407.
32. Ngoi NYL, Tang TY, Gaspar CF, Pavlick DC, Buchold GM, Scholefield EL, Parimi V, Huang RSP, Janovitz T, Danziger N, Levy MA, Pant S, De Armas AD, Kumpula D, Ross JS, Javle M, Rodon Ahnert J. Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers. Oncologist 29(6):493-503, 2024. e-Pub 2024. PMID: 38330461.
33. Rodon Ahnert, J, Damian, S, Furqan, M, Garcia-Donas, J, Imai, H, Italiano, A, Spanggaard, I, Ueno, M, Yokota, T, Veronese, ML, Oliveira, N, Li, X, Gilmartin, AG, Schaffer, M, Goyal, L. Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations. Nature medicine 30(6):1645-1654, 2024. e-Pub 2024. PMID: 38710951.
34. Gouda, MA, Shunyakova, J, Naing, A, Ileana Dumbrava, EE, Hong, DS, Yuan, Y, Yang, P, Myers, AL, Liang, Y, Peng, J, Karp, DD, Tsimberidou, AM, Rodon Ahnert, J, Yap, TA, Piha-Paul, SA, Meric-Bernstam, F, Fu, S. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors. ESMO Open 9(6), 2024. e-Pub 2024. PMID: 38914452.
35. DiPeri, TP, Evans, KW, Wang, B, Zhao, M, Akcakanat, A, Raso, G, Rizvi, YQ, Zheng, X, Korkut, A, Varadarajan, K, Uzunparmak, B, Ileana Dumbrava, EE, Pant, S, Ajani, JA, Pohlmann, PR, Jensen, VB, Javle, M, Rodon Ahnert, J, Meric-Bernstam, F. Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer discovery 14(5):828-845, 2024. e-Pub 2024. PMID: 38358339.
36. Hoff, CO, Dal Lago, EA, Siqueira, JM, De Sousa, LG, El-Naggar, AK, Rodon Ahnert, J, Ferrarotto, R. First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma. JCO Precision Oncology 8, 2024. e-Pub 2024. PMID: 38579194.
37. Rodon Ahnert, J, Rodriguez, E, Maitland, ML, Tsai, F, Socinski, MA, Berlin, J, Thomas, JS, Al Baghdadi, T, Wang, IM, Guo, C, Golmakani, M, Clark, LN, Gazdoiu, M, Li, M, Tolcher, AW. A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations. ESMO Open 9(4), 2024. e-Pub 2024. PMID: 38640748.
38. Piha-Paul, SA, Xu, B, Ileana Dumbrava, EE, Fu, S, Karp, DD, Meric-Bernstam, F, Hong, DS, Rodon Ahnert, J, Tsimberidou, AM, Raghav, KS, Ajani, JA, Conley, AP, Mott, FE, Fan, Y, Fan, J, Peng, P, Wang, H, Ni, S, Sun, C, Qiang, X, Levin, WJ, Ngo, B, Ru, QC, Wu, F, Javle, M. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist 29(4):e514-e525, 2024. e-Pub 2024. PMID: 38297981.
39. Janku, F, Choong, GM, Opyrchal, M, Dowlati, A, Hierro, C, Rodon Ahnert, J, Wicki, A, Forster, M, Blagden, S, Yin, J, Reid, JM, Muller, H, Cmiljanović, N, Cmiljanović, V, Adjei, AA. A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors. Cancers 16(6), 2024. e-Pub 2024. PMID: 38539472.
40. Ogoti, BM, Riitho, V, Wildemann, J, Mutono, N, Tesch, J, Rodon Ahnert, J, Harichandran, K, Emanuel, J, Möncke-Buchner, E, Kiambi, S, Oyugi, J, Mureithi, M, Corman, VM, Drosten, C, Thumbi, SM, Müller, MA. Biphasic MERS-CoV Incidence in Nomadic Dromedaries with Putative Transmission to Humans, Kenya, 2022-2023. Emerging Infectious Diseases 30(3):581-585, 2024. e-Pub 2024. PMID: 38407189.
41. Subbiah, V, Coleman, N, Piha-Paul, SA, Tsimberidou, AM, Janku, F, Rodon Ahnert, J, Pant, S, Ileana Dumbrava, EE, Fu, S, Hong, DS, Zhang, S, Sun, M, Jiang, Y, Roszik, J, Song, J, Yuan, Y, Meric-Bernstam, F, Naing, A. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Research Communications 4(2):378-387, 2024. e-Pub 2024. PMID: 38126764.
42. Nowlen, CJ, Daniels, MS, Uzunparmak, B, Ileana Dumbrava, EE, Yuan, Y, Patel, KP, Rayes, N, Harkenrider, J, Wathoo, C, Veazie, J, Luna, KA, Wang, W, Horombe, C, Javle, M, Rodon Ahnert, J, Yap, TA, Arun, BK, Lu, KH, Meric-Bernstam, F. Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing. Journal of Immunotherapy and Precision Oncology 7(1):7-17, 2024. e-Pub 2024. PMID: 38327755.
43. Calfa, C, Calfa, C, Rothe, M, Rothe, M, Mangat, PK, Mangat, PK, Garrett-Mayer, E, Garrett-Mayer, E, Ahn, E, Ahn, E, Burness, ML, Burness, ML, Gogineni, K, Gogineni, K, Rohatgi, N, Rohatgi, N, Al Baghdadi, T, Al Baghdadi, T, Conlin, A, Conlin, A, Gaba, A, Gaba, A, Hamid, O, Hamid, O, Krishnamurthy, J, Krishnamurthy, J, Gavini, NJ, Gavini, NJ, Gold, PJ, Gold, PJ, Rodon Ahnert, J, Rodon Ahnert, J, Rueter, J, Rueter, J, Thota, R, Thota, R, Grantham, GN, Grantham, GN, Hinshaw, DC, Hinshaw, DC, Gregory, A, Gregory, A, Halabi, S, Halabi, S, Schilsky, RL, Schilsky, RL. Sunitinib in Patients with Breast Cancer with FGFR1 or FGFR2 Amplifications or Mutations. JCO Precision Oncology 8, 2024. e-Pub 2024. PMID: 38354330.
44. Knisely A, Ahmed J, Stephen B, Piha-Paul SA, Karp D, Zarifa A, Fu S, Hong DS, Rodon Ahnert J, Yap TA, Tsimberidou AM, Alshawa A, Dumbrava EE, Yang Y, Song J, Meric-Bernstam F, Jazaeri AA, Naing A. Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer 130(3):400-409, 2024. e-Pub 2024. PMID: 37864520.
45. DiPeri, TP, Zhao, M, Evans, KW, Varadarajan, K, Moss, T, Scott, S, Kahle, MP, Byrnes, CC, Chen, H, Lee, SS, Halim, AB, Hirai, H, Wacheck, V, Kwong, L, Rodon Ahnert, J, Javle, M, Meric-Bernstam, F. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. Journal of Hepatology 80(2):322-334, 2024. e-Pub 2024. PMID: 37972659.
46. Coleman, N, Stephen, B, Fu, S, Karp, DD, Subbiah, V, Rodon Ahnert, J, Piha-Paul, SA, Wright, J, Fessahaye, SN, Ouyang, F, Yilmaz, B, Meric-Bernstam, F, Naing, A. Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors. Cancer medicine 13(3), 2024. e-Pub 2024. PMID: 38400671.
47. Garcia-Sanchez P, Romero-Trancón D, Falces-Romero I, Navarro Carrera P, Ruiz-Carrascoso G, Carmena D, Casares Jiménez M, Rivero-Juárez A, Moya L, Rodón J, Esperón F, Pérez-Hernando B, Sánchez-León R, Hurtado-Gallego J, Alcolea S, Sainz T, Calvo C, Méndez-Echevarría A. Zoonosis screening in Spanish immunocompromised children and their pets. Front Vet Sci 11:1425870, 2024. e-Pub 2024. PMID: 39109349.
48. Nelson BE, Tsimberidou AM, Fu X, Fu S, Subbiah V, Sood AK, Rodon J, Karp DD, Blumenschein G, Kopetz S, Pant S, Piha-Paul SA. A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. Oncologist 28(12):e1100-e1292, 2023. e-Pub 2023. PMID: 37311055.
49. Surana R, Gonzalez GN, Rogers J, Hong DS, Yap TA, Rodon J, Naing A, Wolff RA, Smaglo BG, Bernstam FM, Subbiah V, Pant S. Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Trials. J Gastrointest Cancer 54(4):1308-1315, 2023. e-Pub 2023. PMID: 37119430.
50. Denu RA, Yang RK, Lazar AJ, Patel SS, Lewis VO, Roszik J, Livingston JA, Wang WL, Shaw KR, Ratan R, Zarzour MA, Bird J, Raza S, Akdemir KC, Rodon J, Subbiah V, Patel S, Conley AP. Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes. Clin Cancer Res 29(23):4844-4852, 2023. e-Pub 2023. PMID: 37747813.
51. Tang TY, Nichetti F, Kaplan B, Lonardi S, Pietrantonio F, Salvatore L, Vivaldi C, Rimassa L, de Braud F, Rizzato MD, Pavlick D, Chu R, Danner De Armas A, Sharaf R, Sokol E, Rodon J, Ross JS, Javle M, Niger M. Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers. Clin Cancer Res 29(23):4853-4862, 2023. e-Pub 2023. PMID: 37773629.
52. Duvivier HL, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Al Baghdadi T, Alva AS, Dublis SA, Cannon TL, Calfa CJ, Li R, Behl D, Chiu VK, Gold PJ, Marr AS, Mileham KF, Powell SF, Rodon J, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol 41(33):JCO2300702, 2023. e-Pub 2023. PMID: 37561967.
53. Uzunparmak, B, Haymaker, CL, Raso, G, Masciari, S, Wang, LI, Lin, Y, Gorur, A, Kirby, B, Cimo, AM, Kennon, A, Ding, Q, Urschel, G, Yuan, Y, Feng, G, Rizvi, YQ, Hussain, A, Zhu, C, Kim, P, Abbadessa, G, Subbiah, V, Yap, TA, Rodon Ahnert, J, Piha-Paul, SA, Meric-Bernstam, F, Dumbrava, EE. HER2-low expression in patients with advanced or metastatic solid tumors. Annals of Oncology 34(11):1035-1046, 2023. e-Pub 2023. PMID: 37619847.
54. Engstrom LD, Aranda R, Waters L, Moya K, Bowcut V, Vegar L, Trinh D, Hebbert A, Smith CR, Kulyk S, Lawson JD, He L, Hover LD, Fernandez-Banet J, Hallin J, Vanderpool D, Briere DM, Blaj A, Marx MA, Rodon J, Offin M, Arbour KC, Johnson ML, Kwiatkowski DJ, Janne PA, Haddox CL, Papadopoulos KP, Henry JT, Leventakos K, Christensen JG, Shazer R, Olson P. MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer. Cancer Discov 13(11):2412-2431, 2023. e-Pub 2023. PMID: 37552839.
55. Saridogan T, Akcakanat A, Zhao M, Evans KW, Yuca E, Scott S, Kirby BP, Zheng X, Ha MJ, Chen H, Ng PKS, DiPeri TP, Mills GB, Rodon J, Damodaran S, Meric-Bernstam F. Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer. Sci Rep 13(1):20223, 2023. e-Pub 2023. PMID: 37980453.
56. Lopez J, Lai-Kwon J, Molife R, Welsh L, Tunariu N, Roda D, Fernández-García P, Lladó V, McNicholl AG, Rosselló CA, Taylor RJ, Azaro A, Rodon J, Sludden J, Veal GJ, Plummer R, Urruticoechea A, Lahuerta A, Mujika K, Escribá PV. A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma. Br J Cancer 129(5):811-818, 2023. e-Pub 2023. PMID: 37488446.
57. Hanna, GJ, Stathis, A, Lopez-Miranda, E, Racca, F, Quon, D, Leyvraz, S, Hess, D, Keam, B, Rodon Ahnert, J, Ahn, MJ, Kim, HR, Schneeweiss, A, Ribera, JM, DeAngelo, DJ, Garcia, JP, Cortes, J, Schönborn-Kellenberger, O, Weber, D, Pisa, P, Bauer, M, Beni, L, Bobadilla, M, Lehal, R, Vigolo, M, Vogl, FD, Garralda, E. A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors. Cancer Research Communications 3(9):1853-1861, 2023. e-Pub 2023. PMID: 37712875.
58. Stephen, B, Hajjar, J, Sarda, S, Duose, D, Conroy, J, Morrison, C, Alshawa, A, Xu, M, Zarifa, A, Patel, SP, Yuan, Y, Kwiatkowski, E, Wang, L, Rodon Ahnert, J, Fu, S, Meric-Bernstam, F, Lowman, G, Looney, TJ, Naing, A. T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy. Journal for immunotherapy of cancer 11(8), 2023. e-Pub 2023. PMID: 37604642.
59. Rodon Ahnert, J, Tan, DS, Garrido-Laguna, I, Harb, WA, Bessudo, A, Beck, JT, Rottey, S, Bahary, N, Kotecki, N, Zhu, Z, Deng, S, Kowalski, K, Wei, C, Pathan, N, Laliberté, RJ, Messersmith, WA. Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma. ESMO Open 8(4), 2023. e-Pub 2023. PMID: 37379764.
60. El-Khoueiry AB, Clarke J, Neff T, Crossman T, Ratia N, Rathi C, Noto P, Tarkar A, Garrido-Laguna I, Calvo E, Rodon J, Tran B, O'Dwyer PJ, Cuker A, Abdul Razak AR. Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors. Br J Cancer 129(2):309-317, 2023. e-Pub 2023. PMID: 37237172.
61. Johnson A, Ng PK, Kahle M, Castillo J, Amador B, Wang Y, Zeng J, Holla V, Vu T, Su F, Kim SH, Conway T, Jiang X, Chen K, Shaw KRM, Yap TA, Rodon J, Mills GB, Meric-Bernstam F. Actionability classification of variants of unknown significance correlates with functional effect. NPJ Precis Oncol 7(1):67, 2023. e-Pub 2023. PMID: 37454202.
62. Pestana RC, Moyers JT, Roszik J, Sen S, Hong DS, Naing A, Herzog CE, Fu S, Piha-Paul SA, Rodon J, Yap TA, Karp DD, Tsimberidou AM, Pant S, Zarzour MA, Ratan R, Ravi V, Benjamin RS, Lazar AJ, W-L W, Daw N, Gill JB, Harrison DJ, Lewis VO, Roland CL, Patel SR, Livingston JA, Somaiah N, Ludwig JA, Conley AP, Hamerschlak N, Gorlick R, Meric-Bernstam F, Subbiah V. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res 29(9):1708-1718, 2023. e-Pub 2023. PMID: 37058010.
63. Alhalabi O, Groisberg R, Zinner R, Hahn AW, Naing A, Zhang S, Tsimberidou AM, Rodon J, Fu S, Yap TA, Hong DS, Sun M, Jiang Y, Pant S, Shah AY, Zurita A, Tannir NM, Vikram R, Roszik J, Meric-Bernstam F, Subbiah V. Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ Precis Oncol 7(1):37, 2023. e-Pub 2023. PMID: 37072571.
64. Kuzbari Z, Bandlamudi C, Loveday C, Garrett A, Mehine M, George A, Hanson H, Snape K, Kulkarni A, Allen S, Jezdic S, Ferrandino R, Westphalen CB, Castro E, Rodon J, Mateo J, Burghel GJ, Berger MF, Mandelker D, Turnbull C. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations. Ann Oncol 34(3):215-227, 2023. e-Pub 2023. PMID: 36529447.
65. Son J, Lin HY, Fu S, Biter AB, Dumbrava EE, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Yap TA, Frumovitz MM, Jazaeri AA, Ramirez PT, Westin SN, Yuan Y, Meric-Bernstam F, Hong DS. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol 6(1):10-18, 2023. e-Pub 2023. PMID: 36751659.
66. Moyers JT, Pestana RC, Roszik J, Hong DS, Naing A, Fu S, Piha-Paul S, Yap TA, Daniel K, Rodon J, Livingston A, Zarzour MA, Ravi V, Patel S, Benjamin RS, Ludwig J, Herzog C, Ratan R, Somaiah N, Conley A, Gorlick R, Meric-Bernstam F, Subbiah V. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res 29(2):401-409, 2023. e-Pub 2023. PMID: 36288393.
67. Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med 29(1):115-126, 2023. e-Pub 2023. PMID: 36658425.
68. Mendoza, TR, Hong, DS, Peterson, CB, Stephen, B, Ileana Dumbrava, EE, Pant, S, Tsimberidou, AM, Yap, TA, Sheshadri, A, Altan, M, George, GC, Castillo, L, Rodriguez, E, Gong, J, Subbiah, V, Janku, F, Fu, S, Piha-Paul, SA, Rodon Ahnert, J, Karp, DD, Cleeland, C, Meric-Bernstam, F, Naing, A. Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Scientific reports 12(1), 2022. e-Pub 2022. PMID: 35999229.
69. Ngoi, NY, Pilie, PG, Piha-Paul, SA, Dumbrava, EE, Fu, S, Hong, DS, Karp, DD, Naing, A, Pant, S, Rodon Ahnert, J, Subbiah, V, Tsimberidou, AM, Salguero, C, Brown, CV, Hoadley, WE, Johnson, A, Yuan, Y, Westin, SN, Meric-Bernstam, F, Yap, TA. DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial. European Journal of Cancer 174:S10, 2022. e-Pub 2022.
70. Saggu, G, Stroopinsky, D, Dudek, AZ, Olszanski, AJ, Juric, D, Dowlati, A, Vaishampayan, U, Assad, H, Rodon Ahnert, J, Gibbs, J, Green, J, Du, Z, Rudicell, R, Kannan, K, Gharavi, R, Gomez-Pinillos, A, Fram, RJ, Berger, A, Sachsenmeier, K, Kasar, SN. Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study. European Journal of Cancer 174:S125-S126, 2022. e-Pub 2022.
71. Yap, TA, Ngoi, NY, Dumbrava, EE, Karp, DD, Rodon Ahnert, J, Fu, S, Hong, DS, Naing, A, Pant, S, Piha-Paul, SA, Subbiah, V, Tsimberidou, AM, Dufner, D, Rhudy, J, Gore, SD, Ivy, SP, Yuan, Y, Westin, SN, Mills, GB, Meric-Bernstam, F. NCI10329. European Journal of Cancer 174:S7, 2022. e-Pub 2022.
72. Vo HH, Fu S, Hong DS, Karp DD, Piha-Paul S, Subbiah V, Janku F, Naing A, Yap TA, Rodon J, Ajani JA, Cartwright C, Johnson A, Song IW, Beck J, Kahle M, Nogueras-Gonzalez GM, Miller V, Chao C, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AM. Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. NPJ Precis Oncol 6(1):78, 2022. e-Pub 2022. PMID: 36302890.
73. How JA, Jazaeri AA, Fu S, Rodon Ahnert J, Gong J, Stephen B, Ferreira Dalla Pria H, Bhosale P, Johnson A, Yuan Y, Meric-Bernstam F, Naing A. Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials. Cancers (Basel) 14(15):3695, 2022. e-Pub 2022. PMID: 35954359.
74. Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Rodon Ahnert J, Pant S, Ileana Dumbrava EE, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu S. Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Sci Rep 12(1):9701, 2022. e-Pub 2022. PMID: 35610322.
75. Tamborero D, Rodrigo Dienstmann R, Rachid MH, Boekel J, Lopez-Fernandez A, Jonsson M, Razzak A, Brana I, De Petris L, Yachnin J, Baird RD, Loriot Y, Massard C, Martin-Romano P, Opdam F, Schlenk RF, Vernieri C, Masucci M, Villalobos X, Chavarria E, Blamana J, Apolone G, Caldas C, Bergh J, Ernberg I, Frohling S, Garralda E, Karlsson C, Tabernero J, Voest E, Rodon J, Lehtio. Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer 3(5):649, 2022. e-Pub 2022. PMID: 35449310.
76. Yap TA, Bessudo A, Hamilton E, Sachdev J, Patel MR, Rodon J, Evilevitch L, Duncan M, Guo W, Kumar S, Lu S, Dezube BJ, Gabrail N. IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer. J Immunother Cancer 10(3):e003924, 2022. e-Pub 2022. PMID: 35332062.
77. Guimares de Sousa, L, Wang, K, Torman, DK, Binks, BJ, Rubin, ML, Andersen, C, Lewis, WE, Rivera, MJ, Kaya, D, El-Naggar, AK, Hanna, EY, Esmaeli, B, Frank, SJ, Bell, D, Glisson, BS, Rodon Ahnert, J, Meric-Bernstam, F, Lee, JJ, Ferrarotto, R. Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. Cancer 128(3):509-518, 2022. e-Pub 2022. PMID: 34661906.
78. Dev, R, Zhong, L, Zarifa, A, Albittar, A, Rubin, L, Liu, S, Yap, TA, Dalal, S, Hui, D, Karp, DD, Tsimberidou, AM, Piha-Paul, SA, Rodon Ahnert, J, Fu, S, Meric-Bernstam, F, Naing, A. Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients. Investigational New Drugs 40(1):124-133, 2022. e-Pub 2022. PMID: 34559346.
79. Garmezy B, Gheeya J, Lin HY, Huang Y, Kim T, Jiang X, Thein KZ, Pilie PG, Zeineddine F, Wang W, Shaw KR, Rodon J, Shen JP, Yuan Y, Meric-Bernstam F, Chen K, Yap TA. Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. JCO Precis Oncol 6:e2100267, 2022. e-Pub 2022. PMID: 35108036.
80. Tamborero D, Dienstmann R, Rachid MH, Boekel J, Lopez-Fernandez A, Jonsson M, Razzak A, Brana I, De Petris L, Yachnin J, Baird RD, Loriot Y, Massard C, Martin-Romano P, Opdam F, Schlenk RF, Verneiri C, Masucci M, Villalobos X, Chavarria E, Europe Consortium CC, Balmana J, Apolone G, Caldas C, Bergh J, Ernberg I, Frohling S, Garralda E, Karlsson C, Tabernero J, Voest E, Rodon J, Lehtio J. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer 3(2):251-261, 2022. e-Pub 2022. PMID: 35221333.
81. Adams, S, Othus, M, Patel, SP, Miller, KD, Chugh, R, Schuetze, S, Chamberlin, MD, Haley, B, Storniolo, AM, Reddy, MP, Anderson, SA, Zimmerman, CT, O’Dea, AP, Mirshahidi, HR, Rodon Ahnert, J, Brescia, FJ, Hahn, OM, Raymond, JM, Biggs, DD, Connolly, RM, Sharon, E, Korde, L, Gray, R, Mayerson, E, Plets, M, Blanke, CD, Chae, YK, Kurzrock, R. A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer. Clinical Cancer Research 28(2):271-278, 2022. e-Pub 2022. PMID: 34716198.
82. Sánchez-Guixé M, Hierro C, Jiménez J, Viaplana C, Villacampa G, Monelli E, Brasó-Maristany F, Ogbah Z, Parés M, Guzmán M, Grueso J, Rodríguez O, Oliveira M, Azaro A, Garralda E, Tabernero J, Casanovas O, Scaltriti M, Prat A, Dienstmann R, Nuciforo P, Saura C, Graupera M, Vivancos A, Rodon J, Serra V. High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. Clin Cancer Res 28(1):137-149, 2022. e-Pub 2022. PMID: 34593528.
83. Coleman N, Subbiah V, Pant S, Patel K, Roy-Chowdhuri S, Yedururi S, Johnson A, Yap TA, Rodon J, Shaw K, Meric-Bernstam F. Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition. NPJ Precis Oncol 5:99, 2021. e-Pub 2021. PMID: 34853384.
84. Pernas S, Villagrasa P, Vivancos A, Scaltriti M, Rodon J, Burgues O, Nuciforo P, Canes J, Pare L, Duenas M, Vidal M, Cejalvo JM, Perello A, Llommbard-Cussac A, Dorca J, Montano A, Pascual T, Oliveira M, Ribas G, Rapado I, Prat A, Ciruelos E. First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. Front Oncol 11:744112, 2021. e-Pub 2021. PMID: 34804931.
85. Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang R, Dang M, Dai E, Zhang S, Nie F, Zhao S, Guo C, Hamza A, Czerniak B, Cheng C, Siefker-Radtke A, Bhat K, Futreal A, Peng G, Wargo J, Peng W, Kadara H, Ajani J, Swanton C, Litchfield K, Rodon Ahnert J, Gao J, Wang L. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun 12(5606), 2021. e-Pub 2021. PMID: 34556668.
86. Colen RR, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, Mamindla P, Zinn PO, Ng C, Vikram R, Bakas, Peterson CB, Rodon Ahnert J, Subbiah V, Karp DD, Stephen B, Hajjar J, Naing A. Author response to Cunha et al. J Immunother Cancer 9(7):e003299, 2021. e-Pub 2021. PMID: 34315823.
87. Huey RW, George GC, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul S, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon J, Meric-Bernstam F, Shih YT, Hong DS. Patient‐Reported Out‐of‐Pocket Costs and Financial Toxicity During Early‐Phase Oncology Clinical Trials. Oncologist 26(7):588-596, 2021. e-Pub 2021. PMID: 33783054.
88. Al-Zubidi N, Gombos DS, Hong DS, Subbiah V, Fu S, Rodon Ahnert J, Piha-Paul SA, Tsimberidou AM, Karp DD, Meric-Bernstam F, Naing A. Overview of Ocular Side Effects of Selinexor. The Oncologist 26(7):619-623, 2021. e-Pub 2021. PMID: 33728727.
89. Wright SCE, Vasilevski N, Serra V, Rodon J, Eichhorn PJA. Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity. Cancers (Basel) 13(7):1538, 2021. e-Pub 2021. PMID: 33810522.
90. Colen RR, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, Mamindla P, Zinn PO, Ng C, Vikram R, Bakas, Peterson CB, J . Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer 9(4):e001752, 2021. e-Pub 2021. PMID: 33849924.
91. Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Vailati Negaro M, Rodon Ahnert J, Diao L, Wang J, Le X, Meric-Bernstam F, Routbort M, Roeck B, Yang Z, Raymond VM, Lanman RB, Frampton GM, Miller VA, Schrock AB, Albacker LA, Wong K, Cross JB, Heymach JV. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell 37(3):420, 2021. e-Pub 2021. PMID: 32183953.
92. Hou J, Wang Y, Shi L, Chen Y, Xu C, Saeedi A, Pan K, Bohat R, Egan NA, McKenzie JA, Mbofung RM, Williams LJ, Yang Z, Sun M, Liang X, Rodon Ahnert J, Varadarajan N, Yee C, Chen Y, Hwu P, Peng W. Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators. J Immunother Cancer 9(2), 2021. e-Pub 2021. PMID: 33589527.
93. Araya A, Zeng J, Johnson A, Shufean MA, Rodon J, Meric-Bernstam F, Bernstam EV. Rate of change in investigational treatment options: An analysis of reports from a large precision oncology decision support effort. Int J Med Inform, 2020. e-Pub 2020. PMID: 32889387.
94. Mendoza T, Sheshadri A, Altan M, Hess K, George G, Stephen B, Castillo L, Rodriguez E, Gong J, Peterson C, Rodon Ahnert J, Fu S, Piha-Paul SA, Pant S, Dumbrava E, Yap TA, Janku F, Tsimberidou AM, Subbiah V, Karp DD, Zarifa A, McQuinn LM, Cleeland C, Hong DS, Naing A. Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 33097611.
95. Frumovitz M, Westin SN, Salvo G, Zarifa A, Xu M, Yap TA, Rodon AJ, Karp DD, Abonofal A, Jazaeri AA, Naing A. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecol Oncol 158(3):570-575, 2020. e-Pub 2020. PMID: 32534809.
96. Ellingson BM, Yao J, Raymond C, Nathanson DA, Chakhoyan A, Simpson J, Garner JS, Olivero AG, Mueller LU, Rodon J, Gerstner E, Cloughesy TF, Wen PY. Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients With Recurrent High-Grade Glioma. Clin Cancer Res, 2020. e-Pub 2020. PMID: 32269051.
97. Wen PY, Cloughesy TF, Olivero AG, Morrissey KM, Wilson TR, Lu X, Mueller LU, Coimbra AF, Ellingson BM, Gerstner E, Lee EQ, Rodon J. First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma. Clin Cancer Res, 2020. e-Pub 2020. PMID: 31937616.
98. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu S, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Ileana Dumbrava EE, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer, 2020. e-Pub 2020. PMID: 32188704.
99. Wick A, Desjardins A, Suarez C, Forsyth P, Gueorguieva I, Burkholder T, Cleverly AL, Estrem ST, Wang S, Lahn MM, Guba SC, Capper D, Rodon J. Phase 1b/2a Study of Galunisertib, a Small Molecule Inhibitor of Transforming Growth Factor-Beta Receptor I, in Combination With Standard Temozolomide-Based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma. Invest New Drugs, 2020. e-Pub 2020. PMID: 32140889.
100. Sullivan RJ, Hollebecque A, Flaherty KT, Shapiro GI, Rodon Ahnert J, Millward MJ, Zhang W, Gao L, Sykes A, Willard MD, Yu D, Schade AE, Crowe K, Flynn DL, Kaufman MD, Henry JR, Peng SB, Benhadji KA, Conti I, Gordon MS, Tiu RV, Hong DS. A Phase 1 Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer. Mol Cancer Ther 19(2):460-467, 2020. e-Pub 2020. PMID: 31645440.
101. van den Bent M, Azaro A, De Vos F, Sepulveda J, Yung WKF, Wen PY, Lassman AB, Joerger M, Tabatabai G, Rodon J, Tiedt R, Zhao S, Kirsilae T, Cheng Y, Vicente S, Balbin OA, Zhang H, Wick W. A Phase Ib/II, Open-Label, Multicenter Study of INC280 (Capmatinib) Alone and in Combination With Buparlisib (BKM120) in Adult Patients With Recurrent Glioblastoma. J Neurooncol, 2019. e-Pub 2019. PMID: 31776899.
102. Matos I, Martin-Liberal J, Garcia-Ruiz A, Hierro C, Ochoa de Olza M, Viaplana C, Azaro A, Vieito M, Brana I, Mur G, Ros J, Mateos J, Villacampa G, Berche R, Oliveira M, Alsina M, Elez E, Oaknin A, Munoz-Couselo E, Carles J, Felip E, Rodon J, Tabernero J, Dienstmann R, Perez-Lopez R, Garralda E. Capturing Hyperprogressive Disease With Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria. Clin Cancer Res, 2019. e-Pub 2019. PMID: 31757877.
103. Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisenga M, Poteete A, Sun H, Li S, Chen T, Han H, Vailati Negaro M, Rodon Ahnert J, Diao L, Wang J, Le X, Meric-Bernstam F, Routbort M, Roeck B, Yang Z, Raymond VM, Lanman RB, Frampton GM, Miller VA, Schrock AB, Albacker LA, Wong K, Cross JB, Heymach JV. Pan-cancer landscape and functional analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity. Cancer Cell 36(4):444-457, 2019. e-Pub 2019. PMID: 31588020.
104. Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing A. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer 7(1):253, 2019. e-Pub 2019. PMID: 31533818.
105. Bardia A, Gounder M, Rodon J, Janku F, Lolkema MP, Stephenson JJ, Bedard PL, Schuler M, Sessa C, LoRusso P, Thomas M, Maacke H, Evans H, Sun Y, Tan DSW. Phase Ib Study of Combination Therapy With MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients With Advanced Solid Tumors With RAS/RAF Alterations. Oncologist, 2019. e-Pub 2019. PMID: 31395751.
106. Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña I, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, Martini JF, Raynaud J, Mendelsohn J, Batist G, Onn A, Tabernero J, Schilsky RL, Lazar V, Lee JJ, Kurzrock R. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med 25(5):751-758, 2019. e-Pub 2019. PMID: 31011205.
107. Ileana Dumbrava E, Brusco L, Daniels M, Wathoo C, Shaw K, Lu K, Zheng X, Strong L, Litton J, Arun B, Eterovic AK, Routbort M, Patel K, Qi Y, Piha-Paul S, Subbiah V, Hong D, Rodon J, Kopetz S, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Expanded Analysis of Secondary Germline Findings From Matched Tumor/Normal Sequencing Identifies Additional Clinically Significant Mutations. JCO Precis Oncol, 2019. e-Pub 2019. PMID: 31517177.
108. Harding JJ, Bauer TM, Tan DSW, Bedard PL, Rodon J, Doi T, Schnell C, Iyer V, Baffert F, Radhakrishnan R, Fabre C, Juric D. Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor. Invest New Drugs 37(2):271-281, 2019. e-Pub 2019. PMID: 30073466.
109. Juric D, Janku F, Rodón J, Burris HA, Mayer IA, Schuler M, Seggewiss-Bernhardt R, Gil-Martin M, Middleton MR, Baselga J, Bootle D, Demanse D, Blumenstein L, Schumacher K, Huang A, Quadt C, Rugo HS. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial. JAMA Oncol 5(2):e184475, 2019. e-Pub 2019. PMID: 30543347.
110. Garralda E, Dienstmann R, Piris-Gimenez A, Brana I, J <, Tabernero J. New Clinical Trial Designs in the Era of Precision Medicine. Mol Oncol 13(3):549-557, 2019. e-Pub 2019. PMID: 30698321.
111. Sankhala K, Takimoto CH, Mita AC, Xiong H, Rodón J, Mehrvarz Sarshekeh A, Burns K, Iizuka K, Kopetz S. Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules. Invest New Drugs 37(1):76-86, 2019. e-Pub 2019. PMID: 29667134.
112. Rodon Ahnert J, Gray N, Mok T, Gainor J. What It Takes to Improve a First-Generation Inhibitor to a Second- or Third-Generation Small Molecule. Am Soc Clin Oncol Educ Book 39:196-205, 2019. e-Pub 2019. PMID: 31099659.
113. Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovic S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565(7738):240-245, 2019. e-Pub 2019. PMID: 30568303.
114. Lukas RV, Rodon J, Becker K, Wong ET, Shih K, Touat M, Fassò M, Osborne S, Molinero L, O'Hear C, Grossman W, Baehring J. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J Neurooncol 140(2):317-328, 2018. e-Pub 2018. PMID: 30073642.
115. Mir O, Azaro A, Merchan J, Chugh R, Trent J, Rodon J, Ohnmacht U, Diener JT, Smith C, Yuen E, Oakley GJ, Le Cesne A, Soria JC, Benhadji KA, Massard C. Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours. Eur J Cancer 103:88-97, 2018. e-Pub 2018. PMID: 30218977.
116. Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A. Identification of tumor antigens among the HLA peptidomes of Glioblastoma tumors and plasma. Mol Cell Proteomics 17(11):2132-2145, 2018. e-Pub 2018. PMID: 30072578.
117. Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, Keedy V, Bielle F, Hofheinz RD, Joly F, Blay JY, Chau I, Puzanov I, Raje NS, Wolf J, DeAngelis LM, Makrutzki M, Riehl T, Pitcher B, Baselga J, Hyman DM. BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study. J Clin Oncol:JCO2018789990. e-Pub 2018. PMID: 30351999.
118. Massard C, Azaro A, Soria JC, Lassen U, Le Tourneau C, Sarker D, Smith C, Ohnmacht U, Oakley G, Patel BKR, Yuen ESM, Benhadji KA, Rodon J. First-in-human study of LY3039478, an Oral Notch signaling inhibitor in advanced or metastatic cancer. Ann Oncol 29(9):1911-1917, 2018. e-Pub 2018. PMID: 30060061.
119. Rodon J, Pérez-Fidalgo A, Krop IE, Burris H, Guerrero-Zotano A, Britten CD, Becerra C, Schellens J, Richards DA, Schuler M, Abu-Khalaf M, Johnson FM, Ranson M, Edenfield J, Silva AP, Hackl W, Quadt C, Demanse D, Duval V, Baselga J. Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. Cancer Chemother Pharmacol 82(2):285-298. e-Pub 2018. PMID: 29882016.
120. Wicki A, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanovic N, Cmiljanovic V, Stumm M, Dimitrijevic S, Herrmann R, Prêtre V, Ritschard R, Tzankov A, Hess V, Childs A, Hierro C, Rodon J, Hess D, Joerger M, von Moos R, Sessa C, Kristeleit R. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). Eur J Cancer 96:6-16, 2018. e-Pub 2018. PMID: 29660598.
121. Edelman G, Rodon J, Lager J, Castell C, Jiang J, Van Allen EM, Wagle N, Lindeman NI, Sholl LM, Shapiro GI. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors. Oncologist 23(4):401-e38, 2018. e-Pub 2018. PMID: 29593099.
122. Tamborero D, Rubio-Perez C, Deu-Pons J, Schroeder MP, Vivancos A, Rovira A, Tusquets I, Albanell J, Rodon J, Tabernero J, de Torres C, Dienstmann R, Gonzalez-Perez A, Lopez-Bigas N. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. Genome Med 10(1):25, 2018. e-Pub 2018. PMID: 29592813.
123. Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Demanse D, Blumenstein L, Coughlin C, Quadt C, Baselga J. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. J Clin Oncol 36(13):1291-1299, 2018. e-Pub 2018. PMID: 29401002.
124. Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Jr CR, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 7691(554):189-194, 2018. e-Pub 2018. PMID: 29420467.
125. Meric-Bernstam F, Zheng X, Shariati M, Damodaran S, Wathoo C, Brusco L, Demirhan ME, Tapia C, Eterovic AK, Basho RK, Ueno NT, Janku F, Sahin A, Rodon J, Broaddus R, Kim TB, Mendelsohn J, Mills Shaw KR, Tripathy D, Mills GB, Chen K. Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO Precis Oncol 2018, 2018. e-Pub 2018. PMID: 30035249.
126. Angevin E, Spitaleri G, Rodon J, Dotti K, Isambert N, Salvagni S, Moreno V. A First-in-Human Phase I Study of SAR125844, A Selective MET Tyrosine Kinase Inhibitor, in Patients with Advanced Solid Tumors with MET Amplification. European Journal of Cancer(87):131-139, 2017. e-Pub 2017. PMID: 29145039.
127. Calvo E, Azaro A, Rodon J, Dirix L, Huizing M, Senecal FM, LoRusso P, Yee L. Hepatic Safety Analysis of Trabectedin: Results of a Pharmacokinetic Study With Trabectedin in Patients with Hepatic Impairment and Experience From a Phase 3 Clinical Trial. Investigative New Drugs 36(3):476-486, 2017. e-Pub 2017. PMID: 29177975.
128. Dienstmann R, Elez E, Argiles G, Matos I, Sanz-Garcia E, Ortiz C, Macarulla T, Capdevila J, Alsina M, Sauri T, Verdaguer H, Vilaro M, Ruiz-Pace F, Viaplana C, Garcia A, Landolfi S, Palmer HG, Nuciforo P, Rodon J, Vivancos A, Tabernero J. Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights. Mol Oncol 11(9):1263-1272, 2017. e-Pub 2017. PMID: 28618197.
129. Rodon J, Postel-Vinay S, Hollebecque A, Nuciforo P, Azaro A, Cattan V, Marfai L, Sudey I, Brendel K, Delmas A, Malasse S, Soria JC. First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours. Eur J Cancer 81:142-150, 2017. e-Pub 2017. PMID: 28624695.
130. Hierro C, Alsina M, Sánchez M, Serra V, Rodon J, Tabernero J. Targeting The Fibroblast Growth Factor Receptor 2 in Gastric Cancer: Promise or Pitfall?. Ann Oncology 28(6):1207-1216, 2017. e-Pub 2017. PMID: 28327938.
131. Martin-Liberal J, Rodon J. Clinical Research in Small Genomically Stratified Patient Populations. European Journal of Cancer 80:73-82, 2017. e-Pub 2017. PMID: 28591680.
132. Capper D, von Deimling A, Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, Specenier P, Rodon J, Cleverly A, Smith C, Gueorguieva I, Miles C, Guba SC, Desaiah D, Estrem ST, Lahn MM, Wick W. Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. Int J Mol Sci 18(5), 2017. e-Pub 2017. PMID: 28481241.
133. Martin-Liberal J, Hierro C, Ochoa de Olza M, Rodon J. Immuno-Oncology: The Third Paradigm in Early Drug Development. Target Oncol 12(2):125-138, 2017. e-Pub 2017. PMID: 27995439.
134. Toledo M, Sarria-Estrada S, Quintana M, Maldonado X, Martinez-Ricarte F, Rodon J, Auger C, Aizpurua M, Salas-Puig J, Santamarina E, Martinez-Saez E. Epileptic features and survival in glioblastomas presenting with seizures. Epilepsy Res 130:1-6, 2017. e-Pub 2017. PMID: 28073027.
135. Martin-Liberal J, Ochoa de Olza M, Hierro C, Gros A, Rodon J, Tabernero J. The Expanding Role of Immotherapy. Cancer Treatment Review 54:74-86, 2017. e-Pub 2017. PMID: 28231560.
136. Azaro A, Rodón J, Machiels JP, Rottey S, Damian S, Baird R, Garcia-Corbacho J, Mathijssen RH, Clot PF, Wack C, Shen L, de Jonge MJ. A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function. Cancer Chemother Pharmacol 78(6):1185-1197, 2016. e-Pub 2016. PMID: 27796539.
137. Almhanna K, Kalebic T, Cruz C, Faris JE, Ryan DP, Jung J, Wyant T, Fasanmade AA, Messersmith W, Rodon J. Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies. Clin Cancer Res 22(20):5049-5057, 2016. e-Pub 2016. PMID: 27178743.
138. Cassel JB, Del Fabbro E, Arkenau T, Higginson IJ, Hurst S, Jansen LA, Poklepovic A, Rid A, Rodón J, Strasser F, Miller FG. Phase I Cancer Trials and Palliative Care: Antagonism, Irrelevance, or Synergy?. J Pain Symptom Manage 52(3):437-45, 2016. e-Pub 2016. PMID: 27233136.
139. Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, Capper D, Specenier P, Rodon J, Cleverly A, Smith C, Gueorguieva I, Miles C, Guba SC, Desaiah D, Lahn MM, Wick W. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro Oncol 18(8):1146-56, 2016. e-Pub 2016. PMID: 26902851.
140. Swanton C, Soria JC, Bardelli A, Biankin A, Caldas C, Chandarlapaty S, de Koning L, Dive C, Feunteun J, Leung SY, Marais R, Mardis ER, McGranahan N, Middleton G, Quezada SA, Rodón J, Rosenfeld N, Sotiriou C, André F. Consensus on precision medicine for metastatic cancers: a report from the MAP conference. Ann Oncol 27(8):1443-8, 2016. e-Pub 2016. PMID: 27143638.
141. Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin Cancer Res 22(3):644-56, 2016. e-Pub 2016. PMID: 26224873.
142. Gueorguieva I, Cleverly A, Desaiah D, Azaro A, Seoane J, Braña I, Sicart E, Miles C, Lahn MM, Mitchell MI, Rodon J. Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer. Drugs Context 5:212303, 2016. e-Pub 2016. PMID: 27990167.
143. Toledo M, Sarria-Estrada S, Quintana M, Maldonado X, Martinez-Ricarte F, Rodon J, Auger C, Salas-Puig J, Santamarina E, Martinez-Saez E. Prognostic implications of epilepsy in glioblastomas. Clin Neurol Neurosurg 139:166-71, 2015. e-Pub 2015. PMID: 26489387.
144. De Mattos-Arruda L, Mayor R, Ng CK, Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramon y Cajal S, Carles J, Rodon J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 6:8839, 2015. e-Pub 2015. PMID: 26554728.
145. Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, Zhong B, Platero SJ, Smit JW, Stuyckens K, Chatterjee-Kishore M, Rodon J, Peddareddigari V, Luo FR, Soria JC. Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. J Clin Oncol 33(30):3401-8, 2015. e-Pub 2015. PMID: 26324363.
146. Rodon J, Soria JC, Berger R, Batist G, Tsimberidou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, Miller WH, Eggermont AM, Mendelsohn J, Lazar V, Kurzrock R. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann Oncol 26(8):1791-8, 2015. e-Pub 2015. PMID: 25908602.
147. Brown JR, Davids MS, Rodon J, Abrisqueta P, Kasar SN, Lager J, Jiang J, Egile C, Awan FT. Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma. Clin Cancer Res 21(14):3160-9, 2015. e-Pub 2015. PMID: 25840972.
148. Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, Batist G, Le Chevalier T, Morice P, Besse B, Vassal G, Mortlock A, Hansson J, Berindan-Neagoe I, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget 6(16):14139-52, 2015. e-Pub 2015. PMID: 25944621.
149. Azaro A, Rodon J, Calles A, Braña I, Hidalgo M, Lopez-Casas PP, Munoz M, Westwood P, Miller J, Moser BA, Ohnmacht U, Bumgardner W, Benhadji KA, Calvo E. A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs 33(3):710-9, 2015. e-Pub 2015. PMID: 25902900.
150. Sepulveda-Sanchez J, Ramos A, Hilario A, DE Velasco G, Castellano D, Garcia DE LA Torre M, Rodon J, Lahn MF. Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate. Oncol Lett 9(6):2442-2448, 2015. e-Pub 2015. PMID: 26137087.
151. Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixidó C, Huang A, Ghossein RA, Rosen N, Bivona TG, Scaltriti M, Baselga J. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell 27(4):533-46, 2015. e-Pub 2015. PMID: 25873175.
152. Rodón J, Carducci M, Sepulveda-Sánchez JM, Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I, Cleverly A, Pillay NS, Desaiah D, Estrem ST, Paz-Ares L, Holdhoff M, Blakeley J, Lahn MM, Baselga J. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest New Drugs 33(2):357-70, 2015. e-Pub 2015. PMID: 25529192.
153. Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodón J, Ibrahim Y, Cortes J, Perez-Garcia J, Galvan P, Grueso J, Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandarlapaty S, Scaltriti M, Baselga J. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med 7(283):283ra51, 2015. e-Pub 2015. PMID: 25877889.
154. Rodon J, Carducci MA, Sepulveda-Sánchez JM, Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I, Cleverly AL, Pillay NS, Desaiah D, Estrem ST, Paz-Ares L, Holdhoff M, Blakeley J, Lahn MM, Baselga J. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin Cancer Res 21(3):553-60, 2015. e-Pub 2015. PMID: 25424852.
155. Shou Y, Robinson DM, Amakye DD, Rose KL, Cho YJ, Ligon KL, Sharp T, Haider AS, Bandaru R, Ando Y, Geoerger B, Doz F, Ashley DM, Hargrave DR, Casanova M, Tawbi HA, Rodon J, Thomas AL, Mita AC, MacDonald TJ, Kieran MW. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. Clin Cancer Res 21(3):585-93, 2015. e-Pub 2015. PMID: 25473003.
156. Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Palmer HG, Dawood S, Rodón J, Cajal SR, Campo JM, Felip E, Tabernero J, Cortés J. ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. Sci Rep 5:8179, 2015. e-Pub 2015. PMID: 25670223.
157. Spreafico A, Delord JP, De Mattos-Arruda L, Berge Y, Rodon J, Cottura E, Bedard PL, Akimov M, Lu H, Pain S, Kaag A, Siu LL, Cortes J. A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. Br J Cancer 112(4):650-9, 2015. e-Pub 2015. PMID: 25625276.
158. Bellmunt J, Suarez C, Gallardo E, Rodon J, Pons F, Bonfill T, Beltran M, Moya I, Galtes S, Albanell J, Carles J. Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma. Oncologist 19(9):917-8, 2014. e-Pub 2014. PMID: 25142843.
159. Rodon J, Braña I, Siu LL, De Jonge MJ, Homji N, Mills D, Di Tomaso E, Sarr C, Trandafir L, Massacesi C, Eskens F, Bendell JC. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs 32(4):670-81, 2014. e-Pub 2014. PMID: 24652201.
160. Mahalingam D, Malik L, Beeram M, Rodon J, Sankhala K, Mita A, Benjamin D, Ketchum N, Michalek J, Tolcher A, Wright J, Sarantopoulos J. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma. Cancer Chemother Pharmacol 74(1):77-84, 2014. e-Pub 2014. PMID: 24817603.
161. Gueorguieva I, Cleverly AL, Stauber A, Sada Pillay N, Rodon J, Miles CP, Yingling JM, Lahn MM. Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model. Br J Clin Pharmacol 77(5):796-807, 2014. e-Pub 2014. PMID: 24868575.
162. Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res 20(7):1900-9, 2014. e-Pub 2014. PMID: 24523439.
163. Shapiro GI, Rodon J, Bedell C, Kwak EL, Baselga J, Braña I, Pandya SS, Scheffold C, Laird AD, Nguyen LT, Xu Y, Egile C, Edelman G. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res 20(1):233-45, 2014. e-Pub 2014. PMID: 24166903.
164. Vidwans SJ, Turski ML, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R. A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience 1(10):614-23, 2014. e-Pub 2014. PMID: 25593991.
165. Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Palmer HG, Dawood S, Rodón J, Ramon y Cajal S, Ramony Cajal S, Del Campo JM, Felip E, Tabernero J, Cortés J. Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. Sci Rep 3:3544, 2013. e-Pub 2013. PMID: 24384914.
166. Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, Tao J, Campos AB, Rodon J, Ibrahim YH, Serra V, Rodrik-Outmezguine V, Hazra S, Singh S, Kim P, Quadt C, Liu M, Huang A, Rosen N, Engelman JA, Scaltriti M, Baselga J. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci Transl Med 5(196):196ra99, 2013. e-Pub 2013. PMID: 23903756.
167. De Mattos-Arruda L, RodonJ. Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection. Oncologist 18(11):1180-8, 2013. e-Pub 2013. PMID: 24136009.
168. Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O, Calvo MT, Aura C, Díez O, Rubio IT, Pérez J, Rodón J, Cortés J, Ellisen LW, Scaltriti M, Baselga J. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2(11):1036-47, 2012. e-Pub 2012. PMID: 22915752.
169. Dienstmann R, Serpico D, Rodon J, Saura C, Macarulla T, Elez E, Alsina M, Capdevila J, Perez-Garcia J, Sánchez-Ollé G, Aura C, Prudkin L, Landolfi S, Hernández-Losa J, Vivancos A, Tabernero J. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Mol Cancer Ther 11(9):2062-71, 2012. e-Pub 2012. PMID: 22723336.
170. Calvo E, Vermorken JB, Hiret S, Rodon J, Cortes J, Senellart H, Van den Brande J, Dyck J, Pétain A, Ferre P, Bennouna J. Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors. Cancer Chemother Pharmacol 69(6):1467-75, 2012. e-Pub 2012. PMID: 22382883.
171. Rodon J, Jacobs CD, Chu Q, Rowinsky EK, Lopez-Anaya A, Takimoto CH, Wakelee HA. A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Cancer Chemother Pharmacol 69(3):825-34, 2012. e-Pub 2012. PMID: 22057853.
172. Olmos D, Ang JE, Gomez-Roca C, Morales-Barrera R, Rodon J, Vulink AJ, Massard C, Kaye S, EDDN. Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for phase I oncology trial participants - reply to Fussenich et al.: a new, simple and objective prognostic score for phase I cancer patients. Eur J Cancer 48(4):594-6, 2012. e-Pub 2012. PMID: 22154652.
173. Wakelee HA, Takimoto CH, Lopez-Anaya A, Chu Q, Middleton G, Dunlop D, Ramlau R, Leighl N, Rowinsky EK, Hao D, Zatloukal P, Jacobs CD, Rodon J. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 69(2):563-71, 2012. e-Pub 2012. PMID: 22057855.
174. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, Goldbrunner M, Baselga J. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 30(3):282-90, 2012. e-Pub 2012. PMID: 22162589.
175. Dienstmann R, Rodon J, Tabernero J. Drug development in the era of personalized oncology: from population-based trials to enrichment and prescreening strategies. Am Soc Clin Oncol Educ Book:168-72, 2012. e-Pub 2012. PMID: 24451729.
176. Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodríguez-Braun E, Domingo A, Guijarro J, Gamez C, Rodon J, Di Cosimo S, Brown H, Clark J, Hardwick JS, Beckman RA, Hanley WD, Hsu K, Calvo E, Roselló S, Langdon RB, Baselga J. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 17(19):6304-12, 2011. e-Pub 2011. PMID: 21810918.
177. Huang HJ, Angelo LS, Rodon J, Sun M, Kuenkele KP, Parsons HA, Trent JC, Kurzrock R. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis. PLoS One 6(10):e26060, 2011. e-Pub 2011. PMID: 22022506.
178. Anido J, Sáez-Borderías A, Gonzàlez-Juncà A, Rodón L, Folch G, Carmona MA, Prieto-Sánchez RM, Barba I, Martínez-Sáez E, Prudkin L, Cuartas I, Raventós C, Martínez-Ricarte F, Poca MA, García-Dorado D, Lahn MM, Yingling JM, Rodón J, Sahuquillo J, Baselga J, Seoane J. TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. Cancer Cell 18(6):655-68, 2010. e-Pub 2010. PMID: 21156287.
179. Morales-Barrera R, Valverde C, Rodón J, Pérez J, Maldonado X, Suárez C, Trilla E, Carles J. Bilateral testicular germ cell tumours: a single hospital experience. Clin Transl Oncol 12(4):299-302, 2010. e-Pub 2010. PMID: 20462840.
180. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, Murphy B, Roth B, McCaffery I, Gorski KS, Kaiser B, Zhu M, Deng H, Friberg G, Puzanov I. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 27(34):5800-7, 2009. e-Pub 2009. PMID: 19786654.
181. Lin CC, Calvo E, Papadopoulos KP, Patnaik A, Sarantopoulos J, Mita AC, Preston GG, Mita MM, Rodon J, Mays T, Yeh IT, O’Rourke P, Takimoto CH, Dancey JE, Chen H, Tolcher AW. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 63(6):1065-71, 2009. e-Pub 2009.
182. Rodon J, Iniesta MD, Papadopoulos K. Development of PARP inhibitors in oncology. Expert Opinion Investigative Drugs 18(1):31-43, 2009. e-Pub 2009.
183. Rodon J, Garrison M, Hammond LA, de Bono J, Smith L, Forero L, Hao D, Takimoto C, Lambert JM, Pandite L, Howard M, Xie H, Tolcher AW. Cantuzumab mertansine in a three-times a week Schedule: a phase I and pharmacokinetic study. Cancer Chemother Pharmacol 62(5):911-9, 2008. e-Pub 2008. PMID: 18301896.
184. Rodon J, DeSantos V, Jr FR, Kurzrock R. Early drug Development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 7(9):2575-88, 2008. e-Pub 2008. PMID: 18790742.

Invited Articles

1. Coleman N, Subbiah V, Pant S, Patel K, Roy-Chowdhuri S, Yedururi S, Johnson A, Yap TA, Rodon J, Shaw K, Meric-Bernstam F. Emergence of mTOR as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition. NPJ Precis Oncol 5:99, 2021. e-Pub 2021. PMID: 34853384.
2. Meric-Bernstam F, Johnson AM, Dumbrava EEI, Raghav K, Balaji K, Bhatt M, Murthy RK, Rodon J, Piha-Paul SA. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. Clin Cancer Res 25(7):2033-2041, 2019. e-Pub 2019. PMID: 30442682.
3. Hierro C, Alsina M, Sánchez M, Serra V, b|Rodon J, Tabernero J. Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?. Ann Oncol 29(7):1605, 2018. e-Pub 2018. PMID: 29300805.
4. Kurnit KC, Ileana Dumbrava EE, Litzenburger BC, Khotskaya YB, Johnson A, Yap TA, Rodon J, Zeng J, Shufean MA, Bailey A, Sánchez N, Holla VR, Mendelsohn J, Shaw KRM, Bernstam EV, Mills GB, Meric-Bernstam F. PRECISION ONCOLOGY DECISION SUPPORT: CURRENT APPROACHES AND STRATEGIES FOR THE FUTURE. Clin Cancer Res, 2018. e-Pub 2018. PMID: 29420224.
5. Yates LR, Seoane J, Le Tourneau C, Siu LL, Marais R, Michiels S, Soria JC, Campbell P, Normanno N, Scarpa A, Reis-Filho JS, Rodon J, Swanton C, Andre F. The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. Ann Oncology 1(29):30-35, 2018. e-Pub 2018. PMID: 29140430.
6. Hierro C, Rodon J, Tabernero J. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors. Semin Oncol 42(6):801-19, 2015. e-Pub 2015. PMID: 26615127.
7. Zeron-Medina J, Ochoa de Olza M, Braña I, Rodon J. The Personalization of Therapy: Molecular Profiling Technologies and Their Application. Semin Oncol 42(6):775-87, 2015. e-Pub 2015. PMID: 26615125.
8. Dienstmann R, Rodon J, Barretina J, Tabernero J. Genomic medicine frontier in human solid tumors: prospects and challenges. J Clin Oncol 31(15):1874-84, 2013. e-Pub 2013. PMID: 23589551.
9. Dienstmann R, Rodon J, Tabernero J. Biomarker-driven patient selection for early clinical trials. Curr Opin Oncol 25(3):305-12, 2013. e-Pub 2013. PMID: 23493192.
10. Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 10(3):143-53, 2013. e-Pub 2013. PMID: 23400000.
11. Rodón J, Saura C, Dienstmann R, Vivancos A, Ramón y Cajal S, Baselga J, Tabernero J. Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol 9(6):359-66, 2012. e-Pub 2012. PMID: 22473105.

Review Articles

1. Shah PA, Wiman KG, Cichowski K, Rodon Ahnert J. Capturing Unicorns: Targeting Cancers With TP53 Mutations, RAS Alterations Beyond G12C, and MTAP Loss-No Target Is Out of the Realm of Possibility. Am Soc Clin Oncol Educ Book 45(3):e473616, 2025. e-Pub 2025. PMID: 40435431.
2. Gouda, MA, Ballesteros, PA, Garrido-Laguna, I, Rodon Ahnert, J. Efficacy assessment in phase I clinical trials. Annals of Oncology 36(5):507-519, 2025. e-Pub 2025. PMID: 40049448.
3. Silva, DJ, Nelson, BE, Rodon Ahnert, J. Decentralized Clinical Trials in Early Drug Development—A Framework Proposal. Journal of Immunotherapy and Precision Oncology 7(3):190-200, 2024. e-Pub 2024. PMID: 39219999.
4. Ahmed, J, Torrado, C, Chelariu, A, Kim, S, Rodon Ahnert, J. Fusion Challenges in Solid Tumors. JCO Precision Oncology 8, 2024. e-Pub 2024. PMID: 38986029.
5. Kim MM, Mehta MP, Smart DK, Steeg PS, Hong JA, Espey MG, Prasanna PG, Crandon L, Hodgdon C, Kozak N, Armstrong TS, Morikawa A, Willmarth N, Tanner K, Boire A, Gephart MH, Margolin KA, Hattangadi-Gluth J, Tawbi H, Trifiletti DM, Chung C, Basu-Roy U, Burns R, Oliva ICG, Aizer AA, Anders CK, Davis J, Ahluwalia MS, Chiang V, Li J, Kotecha R, Formenti SC, Ellingson BM, Gondi V, Sperduto PW, Barnholtz-Sloan JS, Rodon J, Lee EQ, Khasraw M, Yeboa DN, Brastianos PK, Galanis E, Coleman CN, Ahmed MM. National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities. Lancet Oncol 24(8):e344-e354, 2023. e-Pub 2023. PMID: 37541280.
6. Rodon J, Funchain P, Laetsch TW, Arkenau HT, Hervieu A, Singer CF, Murciano-Goroff YR, Chawla SP, Anthony K, Yamamiya I, Liu M, Halim AB, Benhadji KA, Takahashi O, Delaloge S. A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations. Future Oncol 18(30):3377-3387, 2022. e-Pub 2022. PMID: 36039910.
7. Hierro C, Azaro A, Argilés G, Elez E, Gómez P, Carles J, Rodon J. Unveiling changes in the landscape of patient populations in cancer early drug development. Oncotarget 8(8):14158-14172, 2017. e-Pub 2017. PMID: 27835915.
8. Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R. Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. Mol Cancer Ther 15(4):533-47, 2016. e-Pub 2016. PMID: 27009213.
9. González-Cao M, Rodón J, Karachaliou N, Sánchez J, Santarpia M, Viteri S, Pilotto S, Teixidó C, Riso A, Rosell R. Other targeted drugs in melanoma. Ann Transl Med 3(18):266, 2015. e-Pub 2015. PMID: 26605312.
10. Dienstmann R, Rodon J, Tabernero J. Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test. Mol Oncol 9(5):940-50, 2015. e-Pub 2015. PMID: 25081646.
11. de Gramont A, Watson S, Ellis LM, Rodón J, Tabernero J, de Gramont A, Hamilton SR. Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol 12(4):197-212, 2015. e-Pub 2015. PMID: 25421275.
12. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Group PW. Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome. Discov Med 19(103):109-16, 2015. e-Pub 2015. PMID: 25725225.
13. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Group PW. Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies. Discov Med 19(103):101-8, 2015. e-Pub 2015. PMID: 25725224.
14. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Group PW. Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. Discov Med 18(101):323-30, 2014. e-Pub 2014. PMID: 25549703.
15. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Group PW. Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. Discov Med 18(101):331-9, 2014. e-Pub 2014. PMID: 25549704.
16. Dienstmann R, Rodon J, Serra V, Tabernero J. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther 13(5):1021-31, 2014. e-Pub 2014. PMID: 24748656.
17. Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, Tabernero J. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol 25(3):552-63, 2014. e-Pub 2014. PMID: 24265351.
18. Serrano C, Morales R, Suárez C, Núñez I, Valverde C, Rodón J, Humbert J, Padrós O, Carles J. Emerging therapies for urothelial cancer. Cancer Treat Rev 38(4):311-7, 2012. e-Pub 2012. PMID: 22113129.
19. Dienstmann R, Braña I, Rodon J, Tabernero J. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist 16(12):1729-40, 2011. e-Pub 2011. PMID: 22135123.
20. Dienstmann R, Rodon J, Markman B, Tabernero J. Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2. Recent Pat Anticancer Drug Discov 6(2):210-36, 2011. e-Pub 2011. PMID: 21294710.
21. Perez-Garcia J, Morales R, Valverde CM, Rodon J, Suarez C, Semidey ME, Garcia-Patos V, Bartralot R, Serra M, Carles J. Eccrine porocarcinoma presenting with scrotal lymphedema: a case report and review of systemic treatment. Ann Oncol 21(4):907, 2010. e-Pub 2010. PMID: 20089564.
22. Suárez C, Morales R, Muñoz E, Rodón J, Valverde CM, Carles J. Molecular basis for the treatment of renal cell carcinoma. Clin Transl Oncol 12(1):15-21, 2010. e-Pub 2010. PMID: 20080466.
23. Rodon J, Perez J, Kurzrock R. Combining targeted therapies: practical issues to consider at the bench and bedside. Oncologist 15(1):37-50, 2010. e-Pub 2010. PMID: 20080862.
24. Carles J, Morales R, Perez JM, Suárez C, Rodón J, Valverde C. Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities. Eur J Cancer 45 Suppl 1:309-17, 2009. e-Pub 2009. PMID: 19775627.

Other Articles

1. Rodon Ahnert, J, Damian, S, Furqan, M, Garcia-Donas, J, Imai, H, Italiano, A, Spanggaard, I, Ueno, M, Yokota, T, Veronese, ML, Oliveira, N, Li, X, Gilmartin, AG, Schaffer, M, Goyal, L Publisher Correction. Nature medicine 30(8):2377, 2024. PMID: 38789647.

Editorials

1. Subbiah V, Rodon J, Yap TA. Precision oncology: East meets West. Int J Cancer 9(142):1734-1737, 2018. PMID: 29243227.
2. Yap TA, Rodon J. Development of Molecularly Driven Targeted Combination Strategies. Oncologist 12(22):1421-1423, 2017. PMID: 29038233.
3. Rodon J, Tabernero J. Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the Darkness. Cancer Discov 7(7):666-669, 2017. PMID: 28684409.
4. Rodon J. An (only) partially established paradigm of drug development of targeted therapies. Eur J Cancer 50(12):2037-9, 2014. PMID: 24908539.
5. Argilés G, Rodon J, Tabernero J. Depicting the evolving scenario of translational-guided drug development. Clin Transl Oncol 14(12):881-2, 2012. PMID: 23150220.

Abstracts

1. Davidson T, Le H, Campbell E, Ozenne C, Dumbrava E, Fu S, Hong D, Karp D, Naing A, Piha-Paul S, Rodon Ahnert J, Tsimberidou A, Yap T, Meric-Bernstam F, Subbiah V. Clinical trial deserts: US urban vs rural patient enrollment among patients with advanced cancer in phase 1 clinical trials at a major cancer center. ASCO Annual Meeting 2023, 2023. e-Pub 2023.
2. Rodon Ahnert J, Spigel DR, Kremer J, Jin L, Benhadji KA, Gil M, Besse B. A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors. ASCO Annual Meeting 2023, 2023. e-Pub 2023.
3. Gouda M, Ahmed J, Nelson B, Nardo M, Roszik J, Cabanillas M, Hu M, Busaidy N, Sherman S, Dadu R, Naing A, Karp D, Rodon Ahnert J, Hong D, Elamin Y, Blumenschein G, Heymach J, Meric-Bernstam F, Subbiah V. Intrapatient comparative efficacy of selective RET inhibitors using growth modulation index in patients with RET aberrant cancers. ASCO Annual Meeting 2023, 2023. e-Pub 2023.
4. De La Fuente M, Rodon Ahnert J, Yaeger R, Tsai F, Janku F, Butowski N, Allen C, Ammakkanavar N, Taylor J, Michelson G, Kline I, Paz M, Wong K, Shepherd S, Jiang P, Sherman E, Tussay-Lindenberg A. Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with Deadvanced solid and CNS tumors: Results from a phase 1/2a study. ASCO Annual Meeting 2023, 2023. e-Pub 2023.
5. Johnson B, Willis J, Williams C, Wang X, Smith G, You YN, Dumbrava E, Fu S, Karp D, Naing A, Piha-Paul S, Rodon Ahnert J, Tsimberidou A, Yap T, Overman M, Pant S, Hong D, Kopetz S, Meric-Bernstam F, Subbiah V. Molecular landscape and survival outcomes on early phase clinical trials in sporadic young onset colorectal cancer. ASCO Annual Meeting 2023, 2023. e-Pub 2023.
6. Rodon Ahnert J, Gruber JJ, Telli ML, Mita MM, Mita AC, Kim JW, Villalona-Calero MA, Patel M, Yadav SS, Sharma P, Haber T, Symons JL, Seet Q, Dharmadhikari B, Thakkar D, Kwek KY, DiMascio L, Rowinsky EK, Ingram P, Boyd-Kirkup JD. A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors. ASCO Annual Meeting 2023, 2023. e-Pub 2023.
7. Fang W, Cheng Y, Chen Z, Wang W, Yin Y, Li Y, Xu H, Li X, Wainberg Z, Yu G, Mi Y, Rodon Ahnert J, Wang X, Wang X, Diao Y, Yang Y, Lu L, Ge J, Li J, Zhang L. SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study. ASCO Annual Meeting 2023, 2023. e-Pub 2023.
8. Sherman E, De La Fuente M, Yaeger R, Tsai F, Janku F, Butowski N, Allen C, Ammakkanavar N, Taylor J, Samara E, Mould D, Michelson G, Kline I, Paz M, Tussay-Lindenberg A, Wong K, Shepherd S, Jiang P, Rodon Ahnert J. Dose optimization of novel BRAF inhibitor FORE8394 based on PK and efficacy results. ASCO Annual Meeting 2023, 2023. e-Pub 2023.
9. Nardo M, Reilley M, Biter A, Lim JA, Bean S, Nguyen L, Bhosale P, Ager C, Couillault C, Piha-Paul S, Fu S, Tsimberidou A, Yap T, Naing A, Rodon Ahnert J, Subbiah V, Karp D, Curran M, Hong D. Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial. ASCO Annual Meeting 2023, 2023. e-Pub 2023.
10. Iyer G, Deming D, Demeure M, Federman N, McKean M, Lee E, Spira A, Kwiatkowski D, Hussein M, Gordon E, Crockett D, Ganjoo K, Schulte B, Cranmer L, Ding L, Schmid A, Navarro W, Rodon Ahnert J. Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I). ASCO Annual Meeting 2023, 2023. e-Pub 2023.
11. Daud A, Albany C, Velcheti V, Hauke R, Rodon Ahnert J, Karp D, Tsimberidou A, Cohen J, Schmidt E, Wang J, Chan CH, Fu S. First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors. ASCO Annual Meeting 2023, 2023. e-Pub 2023.
12. George GC, Piha-Paul SA, Fu S, Rodon Ahnert J, Tm Y, Subbiah V, Dumbrava E, Tsimberidou A, Pant S, Appleton G, Noor L, Meric-Bernstam F, Cleeland CS, Mendoza TR, Hong DS. Baseline symptom, health status, and health utilities in patients in early-phase clinical trials combining immune checkpoint blockade with other anticancer therapies. ASCO Annual Meeting 2023, 2023. e-Pub 2023.
13. Gaspar CF, Ngoi NY, Tang TY, Ross JS, Pavlick DC, Buchold GM, Pant S, Javle M, |Rodon Ahnert J. Clinical impact of MTAP status in advanced cholangiocarcinoma: Genomic profile and response to treatment. AACR Annual Meeting 2023, 2023. e-Pub 2023.
14. Rodon Ahnert J, Schulte B, Demeure MJ, Deming D, Federman N, McKean MA, Lee E, Spira A, Kwiatkowski DJ, Hussein M, Gordon E, Crockett D, Ganjoo K, Cranmer LD, Schmid AN, Navaro WH, Itri LM, Lyer G. Phase 2, multicenter open-label basket trial of nab-sirolimus for patients with inactivating alterations in TSC1 or TSC2 (PRECISION I). AACR Annual Meeting 2023, 2023. e-Pub 2023.
15. Rodon J, Goyal L, Macarulla Mercade T, Ikeda M, Kondo S, D-Y O, L-Y B, Ueno M, Italiano A, Papadopoulos K, Spigel D, Kizilabash SH, Cosman R, Oh Park J, L-T C, Yokota T, Turk AA, C-Y L, Shroff R, El-Khoueiry A, Satoh T, Hollebecuque A, Borad MJ, Azad N, Jaeckle KA, Loong HH, Adeva J, Yong WP, Zhao J, Liu H, Szpurka AM, Gueorguieva I, Pradhan KR, Xu X, Harding JJ. A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced IDH-mutant cholangiocarcinoma and other solid tumors. AACR Annual Meeting 2023, 2023. e-Pub 2023.
16. Rodon J, Damian S, Furqan M, Garcia-Donas J, Imai H, Italiano A, Spanggaard I, ueno M, yokota T, Veronese L, Oliveira N, Li X, Gilmartin A, Goyal L. Clinical and translational findings of pemigatinib in previously treated solid tumors with activating FGFR1-3 alterations in the FIGHT-207 study. AACR Annual Meeting 2023, 2023. e-Pub 2023.
17. Jeffry Evans TR, Dowlati A, Lopez JS, Milhem MM, Rodon Ahnert J, Spira A, Carvajal RD, Zibelman M, Hazard SJ, Dickson A, Xu L, Cohen H, Bader J, Hurov K, Sharma R, Smethurst D, Papadopoulos KP. Phase 1/2 study of the safety, pharmacokinetics, and preliminary clinical activity of BT7480 in patients with nectin-4 associated advanced malignancies. AACR Annual Meeting, 2023. e-Pub 2023.
18. Ngoi NY, Lin HY, Dumbrava E, Fu S, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Campbell E, Urrutia S, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Dynamic changes in monocyte and reticulocyte counts predict mechanism-based anemia development and recovery during ATR inhibitor treatment in phase I/II trials. AACR Annual Meeting 2023, 2023. e-Pub 2023.
19. Anderson CL, Fabbri G, Jenkins D, Cader Z, Sharma S, Tabatabai A, Balachander S, Roebuck J, Galvin M, Simpson K, Dive C, Rodon Ahnert J, Saeh J. AZD0466, a dual BCL-2/XL targeting nanomedicine, is active in small cell lung cancer models. AACR Annual Meeting 2023, 2023. e-Pub 2023.
20. Nelson BE, Janku F, Fu S, Dumbrava EI, Hong DS, Karp D, Naing A, Rodon J, Tsimberidou A, Amaria RN, Conley A, Damodaran S, Raghav KPS, Kreider BL, Tung D, Varterasian M, Khazaie K, Piha-Paul S. Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. AACR Annual Meeting 2023, 2023. e-Pub 2023.
21. Luke J, Sanborn RE, Rodon J, Patel M, Agarwal P, Friedman E, Peterson C, Kelley H, Wright E, Danaee H, Sun H, Barth C, Reilly T, Redig AJ, Friedman C. Phase 1/2 study of HST-1011, an oral CBL-B inhibitor, alone and in combination with anti-PD1 in patients with advanced solid tumors. AACR Annual Meeting 2023, 2023. e-Pub 2023.
22. Uzunparmak B, Haymaker C, Raso G, Zhu C, Masciari S, Wang L, Kirby B, Lin H, Gorur A, A-M C, Kennon A, Ding Q, Palmieri A, Urschel GE, Yuan Y, Feng G, Rizvi Y, Hussain A, Subbiah V, Yap TA, Rodon-Ahnert J, Piha-Paul SA, Hong DS, Meric-Bernstam F, Dumbrava EE. HER2-low expression in patients with advanced or metastatic solid tumors. AACR Annual Meeting 2023, 2023. e-Pub 2023.
23. Deming DA, Rodon Ahnert J, Demeure MJ, Federman N, McKean M, Lee EK, Spira AI, Kwiatkowski DJ, Hussein MA, Gordon EM, Crockett DG, Ganjoo KN, Schulte B, Cranmer LD, Schmid AN, Navarro WH, Itri LM, Iyer G. Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I). ASCO Gastrointestinal Cancers Symposium 2023, 2023. e-Pub 2023.
24. T-Y T, DeArmas AD, Ross JS, Pavlick DC, Sharaf R, Kaplan BG, Sokol E, Rodon Ahnert J, Javle MM. Landscape of BRAF mutation classes in intrahepatic cholangiocarcinoma. ASCO Gastrointestinal Cancers Symposium 2023, 2023. e-Pub 2023.
25. Haber T, Symons JL, Dharmadhikari B, Müller T, Thakkar D, Ahnert Rodon J, Gruber JJ, Telli M, Mita M, Mita A, Patel M, Wang DY, Kim JW, Yadav SS, Sharma P, MiMascio L, Rowinsky EK, Ingram PJ, Boyd-Kirkup J. Trial in Progress: A phase 1 first-in-human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies. SITC Annual Meeting 2022, 2022. e-Pub 2022.
26. Noelle R, Johnson ML, Rodon J, Zauderer M, Lewis L, Severgnini M, Parker J, Lane M, von Roemeling R, Martin AS, Molloy M, Martell RE, Dai T. Pharmacokinetic and pharmacodynamic data from a Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients with Advanced Solid Tumors. SITC Annual Meeting 2022, 2022. e-Pub 2022.
27. Rodon J, Chaney MF, Cohen JV, Garyantes T, Lin JJ, Lorusso P, Mita A, Mita M, Muller C, Natale C, OrloffM, Papadopoulos KP, Patel SP. Phase 1b study of LNS8801 in combination with pembrolizumab in patients with secondary resistance to immune checkpoint inhibitors. SITC Annual Meeting 2022, 2022. e-Pub 2022.
28. Saggu G, Stroopinsky D, Dudek AZ, Olszanski AJ, Juric D, Dowlati A, Vaishampayan U, Assad H, Rodon J, Gibbs J, Green J, Du Z, Rudicell R, Kannan K, Gharavi R, Gomez-Pinillos A, Fram RJ, Berger A, Sachsenmeier K, Kasar S. Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study. EORTC-NCI-AACR Symposium 2022, 2022. e-Pub 2022.
29. Rodon J. Correlation of clinical, genomic and hematological parameters with ATR inhibitor (ATRi) outcomes in phase I/II clinical trials. ESMO Congress 2022, 2022. e-Pub 2022.
30. Rodon J. A phase Ib/II open-label, nonrandomized study of FGFR inhibitor futibatinib in combination with MEK inhibitor binimetinib in patients with advanced KRAS-mutant cancer. ESMO Congress 2022, 2022. e-Pub 2022.
31. Rodon J. A phase I study of synthetic lethal, IDE397 (MAT2A inhibitor) as a monotherapy and in combination with chemotherapy in advanced solid tumors harboring MTAP deletion. ESMO Congress 2022, 2022. e-Pub 2022.
32. Rodon J. Dose escalation of TAS-117 in patients with advanced solid tumors. ESMO Congress 2022, 2022. e-Pub 2022.
33. Rodon J. Intrahepatic cholangiocarcinoma (iCCA) genomic findings with high versus low tumor mutational burdens. ESMO Congress 2022, 2022. e-Pub 2022.
34. Rodon J. Efficacy of BRAF inhibitor FORE8394 in BRAF V600+ patients. ESMO Congress 2022, 2022. e-Pub 2022.
35. Villalona-Calero MA, Patnaik A, Maki RG, O'Neil B, Abbruzzese JL, Dagogo-Jack I, Devarakonda S, Wahlroos S, C-C L, Fujiwara Y, Terbuch A, Postel-Vinay S, M-E G, Addeo A, Prenen H, Arkenau T, Sacher AG, Liu C, Kormany W, Rodon Ahnert J. Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. ASCO Annual Meeting, 2022. e-Pub 2022.
36. Alhalabi O, Tannir NM, Momin HA, Yilmaz B, Stephen B, Ejezie CL, Moyers JT, Gurses SA, How J, Fu S, Rodon Ahnert J, Hong DS, Piha-Paul SA, Subbiah V, Dumbrava EE, Karp DD, Janku F, Meric-Bernstam F, Naing A. Phase Ib trial of selinexor (SEL) in combination with nivolumab (NIVO) alone or nivolumab plus ipilimumab (NIVO+IPI) in patients (pts) with advanced malignancies: The renal cell carcinoma (RCC) experience. ASCO Annual Meeting, 2022. e-Pub 2022.
37. Burka ME, McKean M, Rodon Ahnert J, Mettu NB, Jones JC, Misleh JG, Ma WW, K-H L, Chiorean G, Pishvaian MJ, Gadgeel SM, McKean HA, Kreider B, Knoerzer D, Groover A, Varterasian ML, Box JA, Emery C, Sullivan RJ. A two-part, phase II, multi-center study of the ERK inhibitor ulixertinib (BVD-523) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (BVD-523-ABC). ASCO Annual Meeting, 2022. e-Pub 2022.
38. Schram AM, Goto K, D-W K, Martin-Romano P, Ou S-H I, O'Kane GM, O'Reilly EM, Umemoto K, Duruisseaux M, Neuzillet C, Opdam F, Rodon Ahnert J, Nagasaka M, Weinberg BA, Macarulla T, Joe AK, Ford J, Stalbovskaya V, Wasserman E, Drilon AE. Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers. ASCO Annual Meeting, 2022. e-Pub 2022.
39. Muller C, Chaney MF, Cohen JV, Garyantes T, Lin JJ, LoRusso P, Mita AC, Mita MM, Natale C, Orloff MM, Papadopoulos KP, Patel SP, Rodon Ahnert J. Phase 1b study of the novel first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in combination with pembrolizumab in patients with immune checkpoint inhibitor (ICI)-relapsed and refractory solid malignancies and dose escalation update. ASCO Annual Meeting, 2022. e-Pub 2022.
40. Coleman N, DiPeri TP, Nguyen D, Naing A, Piha-Paul SA, Tsimberidou AM, Zheng X, Johnson A, Wang W, Shaw KR, Dumbrava EE, Fu S, Rodon Ahnert J, Hong DS, Subbiah V, Yap TA, Luthra R, Patel KP, Meric-Bernstam F. Repeat large panel genomic sequencing identifies actionable alterations and characterizes the genomic landscape in patients with metastatic solid tumors. ASCO Annual Meeting, 2022. e-Pub 2022.
41. Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul SA, More JA, Yilmaz B, Karp DD, Dumbrava EE, Tsimberidou AM, Hong DS, Rodon Ahnert J, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple-negative breast cancer. ASCO Annual Meeting, 2022. e-Pub 2022.
42. Wen PY, Rodon Ahnert J, Powderly JD, Colman H, Matheny SL, Golsorkhi AA, Bihani T, Zhang Y, Kaley TJ. Phase 1/2 dose escalation study of NUV-422, a potent inhibitor of cyclin-dependent kinases 2, 4, and 6, in recurrent or refractory (r/r) high-grade gliomas (HGG) and solid tumors. ASCO Annual Meeting, 2022. e-Pub 2022.
43. Ngoi N, Lin HY, Dumbrava EE, Fu S, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon Ahnert J, Subbiah V, Tsimberidou AM, Campbell E, Hong DS, Meric-Bernstam F, Yuan Y, Yap TA. Baseline predictors of hematological toxicity in patients with advanced cancer treated with ATR inhibitors in phase I/II clinical trials. ASCO Annual Meeting, 2022. e-Pub 2022.
44. Piha-Paul SA, Xu B, Singh Raghav KP, Meric-Bernstam F, Janku F, Dumbrava EE, Fu S, Karp DD, Rodon Ahnert J, Conley AP, Mott F, Ajani JA, Hong DS, Fan Y, Peng P, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. First-in-human, phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors. ASCO Annual Meeting, 2022. e-Pub 2022.
45. Nelson BE, Andersen C, Yuan Y, Hong DS, Naing A, Karp DD, Yap TA, Rodon Ahnert J, Campbell E, Tsimberidou AM, Dumbrava EE, Fu S, Piha-Paul SA, Pant S, Blumenschein GR, Altan M, Tawbi HA, Tannir NM, Meric-Bernstam F, Subbiah V. Effect of immunotherapy and time-of-day infusion chronomodulation on survival in advanced cancers. ASCO Annual Meeting, 2022. e-Pub 2022.
46. T-Y T, Ross JS, Rodon Ahnert J, Javle MM. Genomic profile of intrahepatic cholangiocarcinoma with MTAP loss. ASCO Annual Meeting, 2022. e-Pub 2022.
47. Papadopoulos KP, Dowlati A, Dickson A, Hirschberg S, Westrup S, Upadhyaya P, Cohen H, Hurov K, Watson R, Hazard S, Smethurst D, Rodon Ahnert J. A combined phase I/II study of a novel bicycle tumor-targeted immune cell agonist BT7480 in patients with nectin-4 associated advanced malignancies. ASCO Annual Meeting, 2022. e-Pub 2022.
48. DiPeri TP, Zhao M, Moss T, Kahle M, Rauli P, Lee SS, Halim A, Hirai H, Wacheck V, Benhadji K, Rodon J, Javle M, Meric-Bernstam F. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in cholangiocarcinoma with FGFR fusions/rearrangements. AACR Annual Meeting, 2022. e-Pub 2022.
49. Chen MK, Gao Y, Xia W, Y-H W, Litton JK, Y-Y C, Meric-Bernstam F, Piwnica-Worms H, Arun B, Rodon Ahnert J, Wei Y, W-C C, H-L W, Tapia C, Albarracin CT, S-C W, Y-N W, Hortobagyi GN, Lin C, Yang L, Yu D, M-C H. FGFR3 mediated PARP1 tyrosine 158 phosphorylation promotes PARP inhibitor resistance. AACR Annual Meeting, 2022. e-Pub 2022.
50. Gulati GS, Cacheris W, Dutta R, Rodon Ahnert J. Landscape of TSC1 and TSC2 mutations in patients with advanced solid cancers. AACR Annual Meeting, 2022. e-Pub 2022.
51. Surana R, Rogers JE, Nogueras-Gonzalez GM, Hong DS, Yap TA, Rodon Ahnert J, Naing A, Wolff RA, Smalgo BG, Meric-Bernstam F, Subbiah V, Pant S. Prognostic factors associated with survival in patients with pancreatic cancer treated on early phase immune-checkpoint inhibitor clinical trials. ASCO Gastrointestinal Cancers Symposium, 2022. e-Pub 2022.
52. Ngoi N, Scholefiled EL, Parini V, Huang RSP, Janovitz T, Danziger N, Levy MA, Pant S, Javle MM, Ross JS, Rodon Ahnert J. Genomic classification of clinically advanced pancreatic ductal adenocarcinoma (PDAC) based on methylthioadenosine phosphorylase (MTAP) genomic loss (MTAP loss). ASCO Gastrointestinal Cancers Symposium, 2022. e-Pub 2022.
53. Rodon J, Tan DW, Garrido Laguna I, Wael H, Beck JT. Avelumab + binimetinib in metastatic pancreatic ductal adenocarcinoma (mPDAC): dose-escalation results from the phase 1b/2 JAVELIN PARP MEKi trial. SITC Annual Meeting 2021, 2021. e-Pub 2021.
54. Rodon J, Funchain P, Laetsch TW, Singer CF, Arkenau H, Chawla SP, Hervieu A, Yamamiya I, Liu M, Benhadji KA, Takahashi O, Delaloge S. A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN inactivating mutations. ESMO Annual Meeting 2021, 2021. e-Pub 2021.
55. Moyers J, Nguyen D, Hong DS, Ileana Dumbrava E, Fu S, Karp D, Naing A, Pant S, Janku F, Piha-Paul S, J <, Subbiah V, Tsimberidou AM, Meric-Bernstam F, Yap TA. Adherence to the Food and Drug Administration (FDA) Guidance for the Co-Development of Two or More Investigational New Drugs in Phase 1/2 Cancer Trials. ESMO Annual Meeting 2021, 2021. e-Pub 2021.
56. Rodon J. An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors. ESMO Annual Meeting 2021, 2021. e-Pub 2021.
57. Burton E, Ileana Dumbrava EE, Peng W, Milton D, Amaria R, Mcquade J, Glitza IC, Hong D, Patel S, Rodon J, Yap TA, Naing A, Piha-Paul SA, Balmes G, Lazar A, Meric-Bernstam F, Hwu P, Davies MA, Tawbi HA. Ph I/II study of PI3K-β inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors. ESMO Annual Meeting 2021, 2021. e-Pub 2021.
58. George GC, Kim AJ, Gebremeskel M, Manandhar M, Predeep HM, Piha-Paul SA, Rodon Ahnert J, Subbiah V, Karp DD, Cleeland CS, Hong DS. Compliance with Dietary Guidelines and Its Relationship with Symptoms and Clinical Outcomes in Patients with Advanced Cancer in Early-Phase Oncology Clinical Trials. 2021 ASCO Quality Care Symposium, 2021. e-Pub 2021.
59. Piha-Paul SA, Xu B, Janku F, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon Ahnert J, Tsimberidou AM, Javle MM, Fan Y, Peng P, Levin WJ, Ngo B, Wang H, Sun C, Fu QC, Wu F. Phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
60. Schram AM, Rodon Ahnert J, Patel MR, Jauhari S, Sachdev JC, Weijia Zhu V, LoRusso P, Nguyen D, Le X, O'Connor M, Waters N, Cook C, Witt K, Humphrey RW, Janne PA, Hamilton EP. Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
61. Rodon Ahnert J, Augusto Perez C, Man Wong K, Maitland ML, Tsai F, Berlin J, Hsin Liao K, Wang I, Markovtsova L, Jacobs IA, Cavazos N, Li M, Tolcher AW. PF‑06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
62. Coleman N, Naing A, Zhang S, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EE, Fu S, Hong DS, Meric-Bernstam F, Subbiah V. Phase I study of mTORC1/2 inhibitor sapanisertib (TAK-228) in combination with metformin in patients (pts) with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
63. Muller C, Brown-Glaberman UA, Chaney MF, Garyantes T, LoRusso P, McQuade JL, Mita AC, Mita MM, Natale C, Orloff M, Papadopoulos KP, Sato T, Yilmaz E, Rodon J. Phase 1 trial of a novel, first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in patients with advanced or recurrent treatment-refractory solid malignancies. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
64. Dudek AZ, Juric D, Dowlati A, Seymour EK, Rodon Ahnert J, Wang B, Huszar D, Berger AJ, Friedlander S, Gomez-Pinillos A, Proscurshim I, Olsanski AJ. Phase 1/2 study of the novel SUMOylation inhibitor TAK-981 in adult patients (pts) with advanced or metastatic solid tumors or relapsed/refractory (RR) hematologic malignancies. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
65. Lopez Miranda E, Stathis A, Hess D, Racca F, Quon D, Rodon J, Santa Gadea OS, Perez Garcia JM, Nuciforo P, Vivancos A, Cortes J, Ferrarotto R, Schonborn-Kellenberger O, Vigolo M, Bobadilla M, Beni L, Lehal R, Pascal Bauer M, Vogl FD, Garralda E. Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL-NICD gene transcription factor complex in human cancers. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
66. Hiep Vo H, Fu S, Hong DS, Karp DD, Piha-Paul SA, Subbiah V, Janku F, Naing A, Yap TA, Rodon Ahnert J, Ajani JA, Cartwright C, Faraz Naqvi M, Nogueras-Gonzalez GM, Miller VA, Palmer GA, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AM. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT2): Challenges and Opportunities in Conducting an MD Anderson Randomized Study in Precision Oncology. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
67. Yap TA, Dumbrava EE, Rodon Ahnert J, Hong DS, Pant S, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Fu S, Janku F, Montez S, Ahmad-Taha MT, Guerrero D, Nazarenko NN, Moore Y, Soth M, Kovacs J, Heffernan TP, Jones P. First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
68. Waters N, Patel MR, Schram AM, Rodon Ahnert J, Jauhari S, Sachdev JC, Weijia Zhu V, LoRusso P, Nguyen D, Hong DS, Tarilonte L, Humphrey RW, Janne PA, Hamilton EP, Witt K. Clinical pharmacokinetics of bdtx-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies in MasterKey-01 study. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
69. Guimaraes Sousa L, Wang K, Torman D, Binks B, Andersen C, Lewis WE, Rivera M, Kaya D, El-Nagger AK, Hanna EY, Esmaeli B, Frank SJ, Bell D, Glisson BS, Rodon Ahnert J, Meric-Bernstam F, Lee JJ, Ferrarotto R. Treatment patterns and systemic therapy outcomes for patients with salivary duct carcinoma and adenocarcinoma NOS. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
70. Abo-Zahrah R, Karp DD, Adat A, Yap TA, Fu S, Rodon Ahnert J, Piha-Paul SA, Tsimberidou AM, Naing A, Subbiah V, Dumbrava EE, Overman MJ, Patel SP, Amaria RN, Westin SN, Meric-Bernstam F, Janku F. Patients with advanced solid cancers treated with ERK inhibitors exhibit pseudo-progession in lymphatic nodes. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
71. Schram AM, O'Reilly EM, O'Kane GM, Goto K, Kim D, Neuzillet C, Martin-Romano P, Michael D, Nagasaka M, Rodon J, Weinberg BA, Umemoto K, Ou SI, Macarulla T, De La Fouchardiere C, Joe AK, Wasserman E, Stalbovskaya V, Ford J. Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions. ASCO Annual Meeting 2021, 2021. e-Pub 2021.
72. Johnson A, Ng PK, Kahle M, Castillo J, Amador B, Holla V, Vu T, Huang L, Su F, Kim S, Zeng J, Shufean MA, Conway T, Shaw KR, Yap TA, Rodon J, Meric-Bernstam F. Patient-specific, tiered, variant-level actionability correlates with functional effect in growth survival assay. AACR Annual Meeting 2021, 2021. e-Pub 2021.
73. Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal R, George TJ, Yuan Y, Yamamura Y, Westin S, Xing Y, Ileana Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Rdodon J, Takebe N, Kunos C, Lu K, Keyomarsi K, Meric-Bernstam F. Phase II trial of the Wee1 inhibitor adavosertib in advanced refractory solid tumors with CCNE1 amplification Add to My Itinerary. AACR Annual Meeting 2021, 2021. e-Pub 2021.
74. Coleman N, Abbot C, Somaiah N, Piha-Paul S, Pant S, Rodon J, Call SG, Boyle S, Meric-Bernstam F, Janku F. Whole exome sequencing of tumor tissue and circulating tumor DNA ingastrointestinal stromal tumors (GIST). AACR Annual Meeting 2021, 2021. e-Pub 2021.
75. Alhalabi O, Naing A, Groisberg R, Hahn A, Zhang S, Berkey SC, Tsimberidou AM, Rodon J, Yap TA, Pant S, Shah AS, Zurita-Saavedra A, Tannir N, Meric-Bernstam F, Subbiah V. Phase I study of mTORC1-2 inhibitor sapanisertib (TAK-228) in combination with carboplatin plus paclitaxelin patients with advanced solid malignancies and mTOR pathway alterations. AACR Annual Meeting 2021, 2021. e-Pub 2021.
76. DiPeri TP, Evans KW, Tzeng CD, Kwong L, Kahle MP, Zheng X, Li D, Tran Cao HP, Vu T, Kim S, Su F, Kirby B, Wathoo C, Raso G, Rizvi Y, Wang H, Janku F, Shaw K, Yap T, Javle M, Rodon J, Meric-Bernstam F. The MD Anderson patient-derived xenograft series for modeling precision oncology in biliary tract cancers. AACR Annual Meeting 2021, 2021. e-Pub 2021.
77. Calfa C, Rothe M, Mangat PK, Garrett-Mayer E, Ahn E, Gogineni K, Rohatgi N, Burness ML, Gaba A, Hamid O, Albaghdadi T, Conlin A, Gold P, Rodon J, Thota R, Schilsky RL. Sunitinib (S) in patients (pts) with metastatic breast cancer (mBC) with FGFR1 mutations or amplifications: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. AACR Annual Meeting 2021, 2021. e-Pub 2021.
78. Hou J, Wang Y, Shi L, Chen Y, Xu C, Saeedi A, Pan K, Bohat R, Egan NA, McKenzie JA, Mbofung RM, Williams LJ, Yan Z, Sun M, Liang X, Rodon Ahnert R, Varadarajan N, Yee C, Chen Y, Hwu P, Peng W. The landscape of tumor intrinsic immune regulators revealed by genome-wide CRISPR immune screen integrated with comprehensive clinical data analysis. AACR Annual Meeting 2021, 2021. e-Pub 2021.
79. Pant S, Shah A, Msaouel P, Campbell MT, Tu S, Gao J, Blumenschein GR, Mott F, Le X, Altan M, Meric-Bernstam F, Yap TA, Subbiah V, Rodon J, Glasmacher A, Mulder I, Chisamore MJ, Stevenson A, Tannir NM. Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs). SITC Annual Meeting 2020, 2020. e-Pub 2020.
80. Pant S, Shah A, Msaouel P, Campbell MT, Tu S, Gao J, Blumenschein GR, Mott F, Le X, Altan M, Meric-Bernstam F, Yap TA, Subbiah V, Rodon J, Glasmacher A, Mulder I, Chisamore MJ, Stevenson A, Tannir NM. A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors. SITC Annual Meeting 2020, 2020. e-Pub 2020.
81. Naing A, Karp DD, Piha-Paul SA, Haymaker C, Parra ER, Yang F, Pant S, Hong DS, Fu S, Yap TA, Stephen B, Yang Y, Lin H, Hong Leung C, Daver N, Choi Y, Hajjar J, Wistuba I, Hwu PM, Meric-Bernstam F, Rodon J. Immune correlates associated with clinical outcomes in patients with advanced malignancies treated with avelumab and OX40 agonist. SITC Annual Meeting 2020, 2020. e-Pub 2020.
82. Call SG, Huang HJ, Rodon J, Karp DD, Tsimberidou AM, Naing A, Janku F. Targeted next-generation sequencing (NGS) of 105 cancer-related genes in circulating tumor DNA (ctDNA) from patients with advanced cancers treated with immune checkpoint inhibitors (iCPI). Tumor Immunology and Immunotherapy, 2020. e-Pub 2020.
83. Gouda M, Huang H, Piha-Paul S, Call SG, Karp DD, Fu S, Naing A, Subbiah V, Pant S, Tsimberidou AM, Hong DS, Rodon J, Meric-Bernstam F. Circulating Tumor DNA Dynamics Predict Outcomes of Systemic Therapy in Patients with Advanced Cancers. ENA 2020, 2020. e-Pub 2020.
84. Leary A, Estevez-Garcia P, Sabatier R, Farinas-Madrid L, Perez-Fidalgo JA, Romeo M, Barretina Ginesta MP, Gil-Martin M, Garralda E, Rodon J, Lizcano JM, Munoz Guardiola P, Perez-Montoyo H, Yesta-Velasco M, Cortal M, Domenech C, Alfon J, Ray-Coquard IL, Oaknin A. Phase II of ABTL0812, a pro-autophagic drug, in combination with paclitaxel and carboplatin (P/C) as first-line treatment in advanced/recurrent endometrial cancer. ESMO Virtual Congress 2020, 2020. e-Pub 2020.
85. Gheeya JS, Goswamy R, Garmezy B, Pilie PG, Wang W, Lee S, Javle M, Rodon J, Mills Shaw KR, Meric-Bernstam F, Yap TA. Clinical characteristics and therapeutic implications of PALB2 variants in patients with advanced solid tumors. ESMO Virtual Congress 2020, 2020. e-Pub 2020.
86. Brana I, Loriot Y, Berger R, Rubin E, Rodon J, Miller Jr WH, Tsimberidou AM, Saintigny P, Dienstmann R, Nuciforo PG, Bescos C, Lorente J, Viaplana C, Wunder F, Bresson C, Tabernero J, Schilsky RL, Lazar V, Kurzrock R, Soria J. Genomic and transcriptomic profiling in head and neck tumours to identify treatment options: The WINTHER trial experience. ESMO Virtual Congress 2020, 2020. e-Pub 2020.
87. Johnson ML, El-Khoueiry AB, Hafez N, Lakhani NJ, Mamdani H, Rodon Ahnert J, Sanborn RE, Ho T, Li R, Waldes J, Spira AI. CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer. ASCO Annual Meeting 2020, 2020. e-Pub 2020.
88. Piha-Paul SA, Ileana-Dumbrava E, Janku F, Karp DD, Meric-Bernstam F, Rodon J, Ngo B, Peng P, Wu F. Phase I study of TT-00420, a multiple kinase inhibitor, in patients with triple negative breast cancers and other advanced solid tumors. AACR Annual Meeting 2020, 2020. e-Pub 2020.
89. Pilie PG, Gheeya JS, Kyewalabye K, Goswamy PV, WAni KM, Le H, Campbell E, Sanchez NS, Yang D, Garmezy B, Ileana Dumbrava EE, Rodon Ahnert J, Heffernan T, Holla V, Shaw KR, Meric-Bernstam F, Lazar AJ, Wang W, Yap TA. Identifying functional loss of ATM gene in patients with advanced cancer. ASCO Annual Meeting 2020, 2020. e-Pub 2020.
90. Gouda MA, Huang HJ, Piha-Paul SA, Call SG, Karp DD, Fu S, Naing A, Subbiah V, Pant S, Tsimberidou AM, Hong DS, Rodon Ahnert J, Meric-Bernstam F, Janku F. Genomically Informed Longitudinal Monitoring of Circulating Tumor DNA (ctDNA) Predicts Outcomes of Cancer Therapy. ASCO Annual Meeting 2020, 2020. e-Pub 2020.
91. Garmezy B, Gheeya JS, Thein KZ, Pilie PG, Wang W, Rodon Ahnert J, Shaw KR, Meric-Bernstam F, Yap TA. Correlation of pathogenic POLE mutations with clinical benefit to immune checkpoint inhibitor therapy. ASCO Annual Meeting 2020, 2020. e-Pub 2020.
92. Call SG, Huang HJ, Rodon J, Karp DD, Tsimberidou AM, Naing A, Janku F. Targeted next-generation sequencing (NGS) of 105 cancer-related genes in circulating tumor DNA (ctDNA) from patients with advanced cancers treated with immune checkpoint inhibitors (iCPI). ASCO Annual Meeting 2020, 2020. e-Pub 2020.
93. Nusrat M, Roszik J, Holla V, Cai T, Hong M, Coker O, Johnson B, Rodon Ahnert J, Janku F, Kopetz S, Shaw KR, Meric-Bernstam F, Hong DS. Therapeutic vulnerabilities among KRAS G12C mutant (mut) advanced cancers based on co-alteration (co-alt) patterns. ASCO Annual Meeting 2020, 2020. e-Pub 2020.
94. Huey R, George G, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon Ahnert J, Meric-Bernstam F, Shih YT, Hong DS. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. ASCO Annual Meeting 2020, 2020. e-Pub 2020.
95. Subbiah IM, Buzdar A, Ileana Dumbrava EE, Fu S, Janku F, Karp DD, Naing A, Pant S, Rodon J, Tsimberidou AM, Yap TA, Subbiah V, Meric-Bernstam F, Hong DS. Investigating the disparate enrollment of older adults on phase I clinical trials: evolving participation patterns of patients 65 years and older w advanced cancer on phase I trials. ASCO Annual Meeting 2020, 2020. e-Pub 2020.
96. Avila M, Wathoo C, Zeng J, Andersen C, Yuan Y, Yap TA, Rodon Ahnert J, Meric-Bernstam F. Variety of clinical trial enrollment by actionable tumor suppressor genotype. ASCO Annual Meeting 2020, 2020. e-Pub 2020.
97. Yap TA, Lakhani NJ, Araujo DV, Rodon Ahnert J, Chandana SR, Sharma M, Denis J, Gruosso T, Tremblay G, O'Connor M, Ghosh R, Sinclair S, Wood DL, Nadler PI, Siu LL. AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors. ASCO Annual Meeting 2020, 2020. e-Pub 2020.
98. Murthy R, Sheth R, Subbiah V, Janku F, Naing A, Rodon J, Yap TA, Diab A, Patel SP, Tam A, Gupta S, Meric-Bernstam F. Intratumor immunotherapy utilizing real time radiological image guidance: Early experience from a tertiary cancer center. ASCO Annual Meeting 2020, 2020. e-Pub 2020.
99. Hamilton EP, Patel MR, Rodon J, Hong DS, Schram AM, Janne PA, LoRusso P, Jc S, Ou SH, Buck EA, O'Connor M, Waters N, Witt K, Cook C. Masterkey-01: Phase I/II, open-label multicenter study to assess safety, tolerability, pharmacokinetics, and antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies. ASCO Annual Meeting 2020, 2020. e-Pub 2020.
100. Nusrat M, Tapia C, Call SG, Hong DS, Piha-Paul SA, Subbiah V, Rodon J, Tsimberidou AM, Adat A, Wang Y, Meric-Bernstam F, Overman MJ, Kopetz S, Janku F. Evaluation of cytotoxic T cell infiltration and clinical benefit from PD-L1 checkpoint inhibition among PIK3CA mutant microsatellite stable (MSS) metastatic adenocarcinoma patients. AACR Annual Meeting 2020, 2020. e-Pub 2020.
101. Lakhani NJ, Spreafico A, Tolcher AW, Rodon Ahnert J, Janku F, Chandana SR, Oliva Bernal M, Sharma M, Abdul-Karim RM, Hansen UH, Hansesn L, Poulsen TT, Skartved NJO, Dalal RP, Lantto J, Wood DL, Nadler PI, Siu LL. Phase 1 studies of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3). ASCO Annual Meeting 2020, 2020. e-Pub 2020.
102. Moss TJ, Rodon Ahnert J, Oakley HD, Kahle M, Karp DD, Pant S, Jacob J, Raymond VM, Lanman RB, Kwong L, Routbort M, Soni N, Huang J, Javle MM, Meric-Bernstam F. Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120. ASCO Annual Meeting 2019, 2019. e-Pub 2019.
103. Won HH, Selcuklu SD, Piha-Paul SA, Saura C, Rodon J, Mayer IA, Loi S, Shapiro GI, Lu J, Brufsky A, Zimel C, Melcer M, Scaltriti M, Eli LD, Cutler Jr RE, Lalani AS, Bryce RP, Arteaga C, Meric-Bernstam F, Berger MF, Solit DB, Schram A, Hyman DM. Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT "Basket" Trial. AACR Annual Meeting 2019, 2019. e-Pub 2019.
104. Huey R, George G, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon Ahnert J, Meric-Bernstam F, Shih YT, Hong DS. Out of pocket costs and financial toxicity experienced by patients in early phase clinical trials. ASCO Annual Meeting 2019, 2019. e-Pub 2019.
105. Reilley M, Tsimberidou AM, Piha-Paul SA, Yap TA, Fu S, Naing A, Rodon J, Nguyen LM, Ager C, Meng M, Jayaprakash P, Schmidt M, Baumann M, Meric-Bernstam F, Curran MA, Hong DS. Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors. ASCO Annual Meeting 2019, 2019. e-Pub 2019.
106. Lopez D, Barve M, Wang J, Bullock A, Pectasides E, Vaishampayan U, Spira A, Ulahannan S, Patnaik A, Sanborn R, Cicic D, Ang Q, Bergonio G, Rodon Ahnert J. A phase I study of A166, a novel anti-HER2 antibody-drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2019. e-Pub 2019.
107. Feliz L, Asatiani E, Lihou C, Zhen H, Silverman I, Rodon Ahnert J. FIGHT-207: phase 2 study of pemigatinib in patients with previously treated, locally advanced/metastatic or unresectable solid tumor malignancies harboring activating fibroblast growth factor receptor (FGFR) gene alterations. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2019. e-Pub 2019.
108. Meric-Bernstam F, Chaves J, Oh D, Lee J, Kang Y, Hamilton E, Mayordomo J, Cobleigh M, Vaklavas C, Elimova E, Ajani J, Rodon J, Rowse G, Gray T, Lai R, Hanna A. Safety and efficacy of ZW25, a HER2‑targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2019. e-Pub 2019.
109. Yap TA, Rodon Ahnert J, Piha-Paul SA, Fu S, Janku F, Karp DD, Naing A, Ileana Dumbrava EE, Pant S, Subbiah V, Tsimberidou AM, Hong DS, Rose KM, Xu Q, Vellano CP, Mahendra M, Jones P, Di Francesco ME, Marszalek JR, Meric-Bernstam F. Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors. ASCO Annual Meeting 2019, 2019. e-Pub 2019.
110. Schram AM, Drilon A, Macarulla Mercade T, O'Reilly EM, Rodon Ahnert J, Wolpin BM, Ou SI, Kim D, Yang JC, Lam YCJ, Varga A, de Langen AJ, Witteveen PO, Boni V, Cerea G, Duruisseaux M, Liu SV, Wasserman E, Hyman DM, Tabernero J. A phase 2 basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors. ESMO Congress 2019, 2019. e-Pub 2019.
111. Gabrail NY, Bessudo A, Hamilton EP, Sachdev JC, Patel MR, Rodon Ahnert J, Evilevitch LE, Duncan M, Guo W, Lu S, Dezube BJ, Yap TA. IOLite: Multipart, phase 1b, dose-finding study of the PD-1 inhibitor dostarlimab in combination with the PARP inhibitor niraparib ± bevacizumab (bev), or with platinum-based chemotherapy ± bev for advanced cancer. ASCO Annual Meeting 2019, 2019. e-Pub 2019.
112. Lopez J, Chinde R, Burgess MA, Sato T, Thistlewaite F, Van Tine B, Rodon Ahnert J, Dukes J, Easton R, Marshall S. Trial in progress: First-in-human study of a novel anti-NY-ESO-1–anti-CD3, TCR-based bispecific (IMCnyeso) as monotherapy in NY-ESO-1/LAGE-1A-positive advanced solid tumours (IMCnyeso-101). ESMO Congress 2019, 2019. e-Pub 2019.
113. Pant S, Mulder I, Shah AY, Msaouel P, Altan M, Weinberg J, Stevenson A, Meric-Bernstam F, Yap TA, Subbiah V, Rodon Ahnert J. A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy. ASCO Annual Meeting 2019, 2019. e-Pub 2019.
114. Nain A, Meric-Bernstam F, Karp D, Rodon Ahnert R, Piha-Paul SA, Subbiah V, Hong DS, Pant S, Fu S, Janku F, Yap TA, Tsimberidou AM, Ileana Dumbrava EE, Colen RR, Hess KR, Campbell MT, Tu S, Jimenez C, Habra MA, Varadhachary GR. Pembrolizumab in Advanced Rare Cancers. ESMO Congress 2019, 2019. e-Pub 2019.
115. Spreafico A, Janku F, Rodon Ahnert J, Tolcher AW, Chandana SR, Oliva M, Musalli S, Knauss L, Kragh M, Alifrangis L, Frohlich C, Melander MC, Blondal T, Pedersen MW, Lantto J, Wood D, Nadler PI, Horak ID, Siu LL, Lakhani N. A phase 1 study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3). ESMO Congress 2019, 2019. e-Pub 2019.
116. Kurnit KC, Meric-Bernstam F, Hess K, Coleman RL, Bhosale P, Savelieva K, Janku F, Hong D, Naing A, Pant S, Rodon J, Yap TA, Sood AK, Soliman PT, Gershenson DM, Mills GB, Westin SN. Phase I dose escalation of olaparib (PARP inhibitor) and selumetinib (MEK Inhibitor) combination in solid tumors with Ras pathway alterations. AACR Annual Meeting 2019, 2019. e-Pub 2019.
117. Rodon JA, Taylor MH, O'Reilly EM, Zhang J, Doebele RC, Ben Y, Sharp LL, Boyle WJ, Chang C, Frey G, Chen W, Melnick M, Short JM, Burris HA. A phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors. 2018 ASCO Meeting, 2018. e-Pub 2018.
118. Rodon J, J-C S, Berger R, Miller WH, Lazar V, Rubin E, Tsimberidou AM, Saintigny P, Ackerstein A, Brana I, Loriot Y, Afshar M, Miller VA, Wunder F, Bresson C, J-F M, Mendelsohn J, Schilsky RL, Lee JJ, Kurzrock R. WINTHER: An international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies. 2018 ASCO Meeting, 2018. e-Pub 2018.
119. Kheder E, Hess KR, Xing Y, Cortez MA, Subbiah V, Janku F, Fu S, Naing A, Karp DD, Piha-Paul SA, Yap TA, Pant S, Rodon Ahnert J, Tawbi HA, Welsh JW, Meric-Bernstam F, Hong DS. TP53 mutations and programmed cell death ligand-1 expression in solid tumors: Associations with clinical factors and outcomes. 2018 ASCO Meeting, 2018. e-Pub 2018.
120. Azaro A, Rodon J, Middleton MR, Baird RD, Herrmann R, Fielder U, Haunschild J, Häuptle M, Hermann FJ, Schreiner S, Harstrick A, Dawson KM, Omlin AG. First-in-class phase I study evaluating MP0250, a VEGF and HGF neutralizing DARPIN molecule, in patients with advanced solid tumors. 2018 ASCO Meeting, 2018. e-Pub 2018.
121. Piha-Paul SA, Fu S, Hong DS, Janku F, Karp DD, Naing A, Pant S, Rodon Ahnert J, Subbiah V, Tsimberidou AM, Yap TA, Meric-Bernstam F. Phase I study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplification, HER2 mutation/amplification or HER3/4 mutation. 2018 ASCO Meeting, 2018. e-Pub 2018.
122. Merchan JR, Rodon JA, Falchook G, Ostertag D, Tejera D, Gruber HE, Jolly DJ, Shorr J. Toca 6: A phase 1b study of Toca 511 and Toca FC in patients with advanced solid tumors or lymphoma. 2018 ASCO Meeting, 2018. e-Pub 2018.
123. Merchan J, Rodon J, Falchook G, Venkat S, Ostertag D, Tejera D, Kheoh T, Jolly DJ, Gruber HE, Shorr JS. A phase Ib study of Toca 511, a retroviral replicating vector, followed by Toca FC in patients with advanced cancer. AACR Annual Meeting 2018, 2018. e-Pub 2018.
124. Rodon, J, Argiles G, Connolly RM, Vaishampayan U, de Jong M, Garralda E, Giannakis M, Smith DC, Dobson JR, McLaughlin M, Seroutou A, Ji Y, Dolan S, Morawiak J, Moody S, Janku F. Biomarker analyses from a phase I study of WNT974, a first-in-class Porcupine inhibitor, in patients (pts) with advanced solid tumors. AACR Annual Meeting 2018, 2018. e-Pub 2018.
125. Habra M, Campbell M, Jimenez C, Karp D, Hong D, Subbiah V, Pant S, Rodon Ahnert J, Alshawa A, Painter J, Khan S, Rejon M, Stephen B, Tapia C, Mendoza T, Colen R, Hess K, Meric-Bernstam F, Naing A. Efficacy of pembrolizumab in patients with adrenocortical carcinoma. EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, 2018. e-Pub 2018.
126. Bono P, Massard C, Peltola A, Azaro A, Italiano A, Kristeleit RS, Lassen UN, Arkenau HT, Hakulinen P, Garrat C, Ikonen T, Mustonen M, Rodon J. Phase I/II study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours. 43rd ESMO Cancer Congress 2018, 2018. e-Pub 2018.
127. Azaro A, Rodon J, Middleton MR, Baird RD, Herrmann R, Fielder U, Haunschild J, Häuptle M, Hermann FJ, Schreiner S, Harstrick A, Dawson KM, Omlin AG. First-in-class phase I study evaluating MP0250, a VEGF and HGF neutralizing DARPIN molecule, in patients with advanced solid tumors. ASCO Annual Meeting 2018, 2018. e-Pub 2018.
128. Robichaux JP, Elamin YY, Tan Z, Vailati Negrao M, Routbort M, Roeck B, Li S, Liu S, Chen T, Rodon Ahnert J, Diao L, Nilsson MB, Zhang S, Yang Z, Wang J, Meric-Bernstam F, K-K W, Heymach JV. Poziotinib overcomes de novo resistance of HER2 exon 20 mutations in NSCLC and other cancers: Preclinical studies and initial clinical testing. AACR Annual Meeting 2018, 2018. e-Pub 2018.
129. Pant S, Subbiah V, Rodon J, Janku F, Hong DS, Karp D, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Savage RE, Chai F, Yu Y, Schwartz B, Meric-Bernstam F, Yap T. Results of a phase I dose escalation study of ARQ 751 in adult subjects with advanced solid tumors with AKT1, 2, 3 genetic alterations, activating PI3K mutations, PTEN-null, or other known actionable PTEN mutations. AACR Annual Meeting 2018, 2018. e-Pub 2018.
130. Pernas S, Villagrasa P, Vivancos A, Scaltriti M, Rodon J, Burgues O, Nuciforo PG, Canes J, Duenas M, Vidal M, Lluch A, Perello A, Llombart A, Dorca J, Montano A, Oliveira M, Ribas G, Rapado I, Prat A, Cireulos EM. Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study). 43rd ESMO Cancer Congress 2018, 2018. e-Pub 2018.
131. Kheder E, Hess KR, Xing Y, Cortez MA, Subbiah V, Janku F, Fu S, Naing A, Karp DD, Piha-Paul SA, Yap TA, Pant S, Rodon Ahnert J, Tawbi HA, Welsh JW, Meric-Bernstam F, Hong DS. TP53 mutations and programmed cell death ligand-1 expression in solid tumors: Associations with clinical factors and outcomes. ASCO Annual Meeting 2018, 2018. e-Pub 2018.
132. Ferrarotto R, Glisson B, Blumenschein G, Hong D, Piha-Paul S, Rodon Ahnert J, Pant S, Tsimberidou A, Janku F, Alshawa A, Jain D, Rejon M, Hess K, Colen R, Lu C, Stephen B, Tapia C, Mendoza T, Meric-Bernstam F, Naing A. Efficacy of pembrolizumab in patients with cutaneous squamous cell carcinoma. EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, 2018. e-Pub 2018.
133. Pant S, Subbiah V, Rodon J, Janku F, Hong D, Karp D, Piha-Paul S, Tsimberidou AM, Naing A, Fu S, Savage RE, Chai F, Yu Y, Tith K, Alfattal R, Schwartz B, Meric-Bernstam F, Yap T. A phase 1 dose escalation study of ARQ 751 in adult patients with advanced solid tumors with AKT1, 2, 3 genetic alterations, activating PI3 K mutations, PTEN-null, or other known actionable PTEN mutations. EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, 2018. e-Pub 2018.
134. Abida W, Bang Y J, Carter L, Azaro A, Krebs M, S-A I, Chen Y, Buil-Bruna N, Li Y, Eaton D, Stephens C, Ross G, Pass M, Rodon J, Dean E. Phase I modular study of AZD0156, a first-in-class oral selective inhibitor of ataxia telangiectasia mutated protein kinase (ATM), in combination with olaparib (AToM Study, Module 1). 2017 AACR-NCI-EORTC Annual Meeting, 2017. e-Pub 2017.
135. Ileana Dumbrava E, Balaji K, Raghav K, Javle M, Blum-Murphy M, Sajan B, Kopetz S, Broaddus R, Routbort M, Pant S, Tsimberidou A, Subbiah V, Hong D S, Rodon Ahnert J, Shaw K, Piha-Paul S, Meric-Bernstam F. Targeting HER2 (ERBB2) amplification identified by next-generation sequencing (NGS) in patients with advanced or metastatic solid tumors. 2017 AACR-NCI-EORTC Annual Meeting, 2017. e-Pub 2017.
136. Piha-Paul S A, Xiong W W, Moss T, Mostorino R M, Sedelmeier S, Hess K, Fu S, Hong D, Janku F, Karp D, Naing A, Pant S, Rodon J, Subbiah V, Tsimberidou A M, Yap T, Javle M, Tapia C, Shaw K R, Eterovic K, Mills G B, Meric-Bernstam F. Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, aberrations in other BRCA pathway genes, and germline mutations in BRCA1/2 (not breast or ovarian cancer). 2017 AACR-NCI-EORTC Annual Meeting, 2017. e-Pub 2017.
137. Azaro A, Aguilar S, Dienstmann R, Braña I, Hierro C, Ochoa de Olza M, Martin-Liberal J, Vieito M, Matos I, Nuciforo P, Tabernero J, Rodon J, Vivancos A, Garralda E. Evolving molecular prescreening program to identify genomic alterations in the NOTCH pathway. 2017 AACR-NCI-EORTC Annual Meeting, 2017. e-Pub 2017.
138. Yuen E, Bell R, Posada M, Massard C, Rodon J, Smith C, Thorn K, Diener JT, Ortega D, Suico J, Benhadji K. Population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor, LY3039478, in patients with advanced cancer and healthy volunteers. 2017 AACR-NCI-EORTC Annual Meeting, 2017. e-Pub 2017.
139. Hyman DM, Piha-Paul SA, Rodon J, Saura C, Shapiro GI, Quinn DI, Moreno V, Mayer IA, Arteaga C, Boni V, Calvo E, Loi S, Lockhart AC, Smyth LM, Erinjeri J, Scaltriti M, Ulaner G, Torris J, Patel J, Tang J, Meng F, Selcuklu D, Won H, Boluvier N, Berger MF, Jr CR, Xu F, Butturini A, Eli SD, Mann G, Lalani AS, Bryce RP, Meric-Bernstam F, Baselga J, Solit DB. Neratinib in HER2 or HER3 mutant solid tumors: SUMMIT, a global, mulit-histology, open-label, phase 2 'basket' study. Cancer Research; Proceedings of the AACR Annual Meeting 2017 77(19), 2017. e-Pub 2017.
140. Oliveira M, Pascual J, Cruz C, Gris L, Palafox M, Llop A, Castroviejo M, Viaplana C, Ibrahim YH, Arribas J, Cortes J, Baselga J, Rodon J, Balmana J, Dienstmann R, Saura C, Serra V. Patient-derived tumor xenografts (PDXs) recapitulate the antitumor activity of novel therapies in metastatic breast cancer (MBC) patients (pts). Cancer Research; Proceedings of the AACR Annual Meeting 2017 77(19), 2017. e-Pub 2017.
141. Pernas Simon S, Villagrasa Gonzalez P, Vivancos A, Prat A, Scaltriti M, Burgues O, Rodon J, Canes J, Lluch A, Llombart A. AGATA molecular screening program: Implementing precision medicine in patients with advanced breast cancer in Spain. Annals of Oncology, 2017 ESMO Annual Meeting 28(5), 2017. e-Pub 2017.
142. Mir O, Azaro A, Merchan J R, Chugh R, Trent J C, Rodon J, Ohnmacht U, Smith C, Oakley III G J, Le Cesne A, J-C S, Benhadji K, Massard C. Notch pathway inhibition with LY3039478 in soft tissue sarcoma (STS) and gastrointestinal stromal tumours (GIST). Annals of Oncology, 2017 ESMO Annual Meeting 28(5), 2017. e-Pub 2017.
143. Hierro C, Sánchez-Guixé M, Ruiz-Pace F, Jimenez J, Maynes L, Azaro A, Martin-Liberal J, Ochoa de Olza M, Braña I, Vieito M, Villanueva A, Palmer H G, Arribas J, Nuciforo P, Vivancos A, Garralda E, Dienstmann R, Tabernero J, Serra V, Rodon J. FGFR 360° resistance: Establishing a translational research framework in FGFR-altered (FGFRalt) patients (pt) treated with fibroblast growth factor receptor inhibitors (FGFRinh). Annals of Oncology, 2017 ESMO Annual Meeting 28(5), 2017. e-Pub 2017.
144. J-C S, Rodon J, Berger R, Miller W H, Brana I, Loriot Y, Mughal T I, Lazar V, Wunder F, Bresson C, Koscielny S, Afshar M, Saintigny P, Tsimberidou A M, Richon C, Batist G, Onn A, Ackerstein A, Rubin E, Kurzrock R. WINTHER: An International Study to Select Rational Therapeutics Based on the Analysis of Matched Tumor And Normal Biopsies in Subjects with Advanced Malignancies. J Clin Oncol, 2017 ASCO Annual Meeting, 2017. e-Pub 2017.
145. Hyman D M, Kaley T J, Hollebecque A, Subbiah V, Rodon J, Lockhart AC, Keedy V, Hofheinz R, Lobbedez F, Blay J, Chau I, Puzanov I, Raje N, Wolf J, Makrutzki M, Riehl T, Pitcher B, Baselga J. Vemurafenib in Patients with BRAFv600 Mutant Glioma: A Cohort of the Histology-Independent VE-Basket Study. J Clin Oncol, 2017 ASCO Annual Meeting, 2017. e-Pub 2017.
146. Baste N, Dienstmann R, Brana I, Viaplana C, Jimenez J, Ruiz-Pace F, Bescos C, Lorente J, Giralt J, Alberola M, Nuciforo P, Vivancos A, Del Campo J M, Tabernero J, Felip E, Rodon J. Impacts of Early Trials in Molecularly-Characterized Patients (pts) With Head and Neck Cancer (HNC). J Clinical Oncol, 2017 ASCO Annual Meeting, 2017. e-Pub 2017.
147. Azaro A, Plummer E R, Urruticoechea A, Rodon J, Haris N R, Veal G, Perier A, Tur V, Escriba P V, Busquets X, Alberti J, Sicart E, Collins D, Fernandez R, Bettenhaussen E, Klumper E, Lopez J S. Final Report of a Phase 1 Study of 2-Hydroxyoleic Acid (2OHOA) a Novel Sphingomyelin Synthase Activator in Patients (pt) With Advanced Solid Tumors (AST) Including Recurrent Hign Grade Gliomas (rHGG). J Clin Oncol, 2017 ASCO Annual Meeting, 2017. e-Pub 2017.
148. Hong D S, Hollebecque A, Gordon M S, Flaherty K T, Shapiro G, Rodon J, Millward M, Ramdas N, Zhang W, Gao L, Sykes A, Willard M D, Yu D, Schade A, Flynn D L, Kaufman M, S-B P, Conti I, Tiu R V, Sullivan R J. A First-in-Human Dose Phase 1 Study of LY3009120 in Advanced Cancer Patients. J Clin Oncol, 2017 ASCO Annual Meeting, 2017. e-Pub 2017.
149. Hierro C, Serrano M, Ruiz-Pace F, Martin-Liberal J, Ochoa de Olza M, Azaro A, Ir B, Vieito M, Alsina M, Perez Garcia J M, Verdaguer H, Macarulla T, Sanchez M, Serra V, Nuciforo P, Vivancos A, Garralda E, Dienstmann R, Tabernero J, Rodon J. Molecular Markers to Predict Response to Selective Fibroblast Growth Factor Receptor Inhibitors (FGFRinh) in Patients (pts) with FGFR-Amplified (amp) or Mutated (mut) Tumors. J Clin Oncol, 2017 ASCO Annual Meeting, 2017. e-Pub 2017.
150. Chau I, Bendell J C, Calvo E, Santana-Davila R, Rodon Ahnert J, Penel N, H-T A, Yang J, Rege J, Mi G, Ferry D, Herbst R S, Fuchs C S. Interim Safety And Clinical Activity in Patients (PTS) With Advanced Gastric or Gastroesphageal Junction (G/GEJ) Adenocarcinoma From a Multicohort Phase 1 Study of Ramucirumab (R) Plus Pembrolizumab (P). J Clin Oncol, 2017 Gastrointestinal Cancers Symposium, 2017. e-Pub 2017.
151. Dawson K, Feurstein D, Fiedler U, Kuster K, Bez M, Schreiner S, Turner D, Tadjalli Mehr K, Stumpp M, Harstrick A, Baird R, Omlin A, Middleton M, Rodon J, Zitt C. Preliminary biomarker and pharmacokinetic analysis from the completed dose escalation part of the first-in-human Phase I study evaluating MP0250, a multi-DARPin® blocking HGF and VEGF-A, in patients with advanced solid tumors. 2016 AACR-NCI-EORTC Annual Meeting:P085/406, 2016. e-Pub 2016.
152. Azaro A, Ghiglione L, Valdivia C, Munné M, Renedo B, Sabaté N, Alcalde M, Braña I, Hierro C, Martin-Liberal J, Ochoa de Olza M, Martínez G A, Vilaró M, Tabernero J, Rodon J. Early interventions to detect potential drug-drug interactions on patient eligibility for phase 1 clinical trials. 2016 AACR-NCI-EORTC Annual Meeting, 2016. e-Pub 2016.
153. Rodon J, Curigliano G, J-P D, Harb W, Azaro A, Donnet V, Han Y, Blumenstein L, Wilke C, Beck J T. A phase Ib dose-finding study of alpelisib (ALP; BYL719) and paclitaxel (PTX) in advanced solid tumors (aST). Annals of Oncology, 2016 ESMO Annual Meeting 27(6), 2016. e-Pub 2016.
154. Rodon J, Peltola K, Azaro A, Castanon Alvarez E, Garratt C, Leskinen H, Bjorklund H, Ruck A, Massard C, Bono P. Phase 1 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours. Annals of Oncology, 2016 ESMO Annual Meeting 27(6), 2016. e-Pub 2016.
155. Middleton M R, Azaro A, Kumar S, Niedermann P, Rodón J, Herbschleb K H, Steiner J, Zitt C, Feurstein D, Schreiner S, Turner D, Dawson K, Tadjalli-Mehr K, Vom Baur E, Stumpp M, Harstrick A, Baird R, Omlin A. Interim results from the completed first-in-human phase I dose escalation study evaluating MP0250, a multi-DARPin® blocking HGF and VEGF, in patients with advanced solid tumors. Annals of Oncology, 2016 ESMO Annual Meeting 27(6), 2016. e-Pub 2016.
156. Cao M G, Manzano J L, Soriano V, Puertolas T, Soria A, Mayo C, Magem M, Molina M A, Montagut C, Muñoz E, Rodriguez D, Perez E, Garcia A, Cortes J, Jordana N, Rodon J, Karachaliou N, Rosell R. BRAF mutation analysis in cell free tumoral DNA (cfDNA) of melanoma patients: results from the prospective study GEM1304 (Spanish Melanoma Group). Cancer Res, 2016 AACR Annual Meeting 76(14 Supplement):468-468, 2016. e-Pub 2016.
157. Yuen E, Patel B, Smith C, Posada M, Bell R, Ohnmacht U, Massard C, Rodon J, Benhadji K. Population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor, LY3039478, in the first-in-man study. Cancer Res, 2016 AACR Annual Meeting 76(14 Supplement):CT048-CT048, 2016. e-Pub 2016.
158. Hilf N, Frenzel K, Kuttruff-Coqui S, Heesch S, Kreiter S, Admon A, Bukur V, Van Der Burg S, Gouttefangeas C, Kroep J R, Schoenmaekers-Welters M, Piro J, Ponsati B, SkovgaardPoulsen H, Lassen U, Martinez-Ricarte F, Rodon J, Sahuquillo J, Stieglbauer M, Stevanovic S, Straten P, Skardelly M, Tabatabai G, Platten M, Capper D, v DA, Dutoit V, Okada H, Ottensmeier C, Feist R K, Fritsche J, Laske K, Lewandrowski P, Löwer M, Mendryzk R, Meyer M, Reinhardt C, Rössler B, Paruzynski A, Pawlowski N, Song C, Lea S, Weinschenk T, Huber C, H-G R, P-Y D, Wolfgang W, Sahin U, Singh-Jasuja H. GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide vaccination trial in patients with newly diagnosed glioblastoma. Cancer Res, 2016 AACR Annual Meeting 76(14 Supplement):2654-2654, 2016. e-Pub 2016.
159. Lopez J S, Fontes M, Coleman N, Azaro A, Drew Y, Escriba P, Busquets X, Veal G, Tur V, Perier A, Sicart E, Molife R, Plummer R, Rodon J. 2-hydroxyoleic acid (2-OHOA), a novel activator of sphingomyelin synthase with antitumor activity in refractory glioblastoma: results of the first-in-human dose-escalation (DE) study in patients with advanced solid tumors (AST) and refractory gliomas/glioblastomas. Cancer Res, 2016 AACR Annual Meeting 76(14 Supplement):CT067-CT067, 2016. e-Pub 2016.
160. Liberal J M, Martinez de Castro A M, Dienstmann R, Hierro C, Ochoa de Olza M, Brana I, Azaro A, Argiles G, Cruz Zambrano C, Oliveira M, Saura C, Oaknin A, Aguilar H, Sanchez E, Nuciforo P, Vivancos A, Tabernero J, Rodon J. Matching Degree Between P13K/AKT/mTOR (PAM) Pathway Mutations (mut) and Therapy (TTX) as Predictor of Clinical Benefit (ClinBen) in Early Trials. J Clin Oncol, 2016 ASCO Annual Meeting, 2016. e-Pub 2016.
161. Wen P Y, Cloughesy Timothy F, Olivero A, Lu X, Mueller L, Fernandez Coimbra A, Robins Gerstner E, Rodon J. A First-in-Human Phase 1 Study to Evaluate the Brain-Penetrant P13K/mTOR Inhibitor GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma. J Clin Oncol, 2016 ASCO Annual Meeting, 2016. e-Pub 2016.
162. Rodon J, Garratt C, Laapas K, Leskinen H, Bjorklund H, Ruck A, Peltola K, Azaro A, Castanon-Alvarez E, Massard C, Bono P. Dose Escalation Study of ODM-203, A Selective Dual FGFR/VEGFR Inhibitor, in Patients with Advanced Solid Tumours. J Clin Oncol, 2016 ASCO Annual Meeting, 2016. e-Pub 2016.
163. Sauri T, Macarulla T, Cabrera G, Verdaguer H, Zeron-Medina J, Vivancos A, Capdevilla J, Elez E, Alsina M, Argiles G, Hierro C, Grasselli J, Matos I, Rodon J, Nuciforo P, Dienstmann R, Tabernero J. Molecular Prescreening (MP) to Treat Patients (PTS) with Advanced Pancreatic Cancer (PC) in Early Clinical Trials, 2016. e-Pub 2016.
164. Analia A, Argiles G, Alsina M, Elez E, Macarulla T, Cruz C, Marino D, Hierro C, Cedres S, Navarro A, Ochoa de Olza M, Brana I, Martin-Liberal J, Vilaro M, Moreno D, Martinez P Diaz M, Vivancos A, Rodon J, Tabernero J, Prudkin L, Nuciforo P. Prevalence of MET copy number variation, MET expression and MET related genomic alterations in all solid tumors pre-screening program. Mol Cancer Ther, VHIO experience 14(12S2), 2015. e-Pub 2015.
165. Rodon J, Omlin A, Herbschleb KH, Garcia-Corbacho J, Steiner J, Dolado I, Zitt C, Feurstein D, Turner D, Dawson KM, Stumpp MT, Gilboy P, Harstrick A, Azaro A, Ackermann CJ, Middleton MR, Baird RD. First-in-human Phase I study to evaluate MP0250, a DARPin blocking HGF and VEGF, in patients with advanced solid tumors. Mol Cancer Ther 14(12S2), 2015. e-Pub 2015.
166. Janku F, Roisin C, LoRusso P, de Jong M, Vaishampayan U, Rodon J, Argiles G, Myers A, S-F HS, Ji Y, McLaughlin M, Mr P, Morawiak J. Phase I study of WNT974, a first-in-class Porcupine inhibitor, in advanced solid tumors. Mol Cancer Ther 14(12S2), 2015. e-Pub 2015.
167. Grasselli J, Elez E, Sauri T, Macarulla T, Alsina M, Capdevila J, Argiles G, Hierro C, Salva F, Sanz-Garcia E, Racca F, Azaro A, Brana I, Ochoa de Olza M, Grau I, Sala G, Rodon J, Salazar R, Tabernero J. Developmental therapeutics activity portrait in metastatic colorectal cancer (mCRC): Vall d'Hebron Institute of Oncology Program. Ann Oncol 26(4S):iv105-iv106, 2015. e-Pub 2015.
168. Garrido-Castro AC, Argiles G, Moreno D, Vilaro M, Rodriguez-Freixinos V, Macarulla T, Cruz C, Azaro A, Elez E, Alsina M, Perez-Garcia JM, Jimenez J, Nuciforo P, Vivancos A, Seoane J, Del Campo JM, Rodon J, Tabernero J, Oaknin A. Early drug development in advanced gynecologic cancer based on genetic tumor profiling. J Clin Oncol, The 2015 ASCO Annual Meeting 33(15S), 2015. e-Pub 2015.
169. Argiles G, Elez E, Ortiz C, Sanz-Garcia E, Macarulla T, Alsina M, Capdevila J, Azaro A, Cruz C, Hierro C, Vilaro M, Moreno D, Dienstmann R, Landolfi S, Nuciforo P, Vivancos A, Rodon J, Tabernero J. Outcome evolution of matched molecular targeted agents (MTAs) in metastatic colorectal cancer (CRC) patients (pts): VHIO experience. J Clin Oncol, The 2015 ASCO Annual Meeting 33(15S), 2015. e-Pub 2015.
170. Escriba PV, Busquets X, Llado V, Roda D, Jimenez B, Molife R, Plummer R, Rodon J, Azaro A, Sicart E, Klumper E. Pivotal role of sphingomyelin synthase (SGMS) expression and activity in glioma patient survival presents a potential therapeutic target. J Clin Oncol, The 2015 ASCO Annual Meeting 33(15S), 2015. e-Pub 2015.
171. Ortiz C, Argiles G, Elez E, Matito J, Mendizabal L, Lo Giacco D, Mancuso FM, Sanz-Garcia E, Macarulla T, Alsina M, Capdevila J, Sauri T, Azaro A, Cruz C, Hierro C, Cajal SRY, Nuciforo P, Rodon J, Tabernero J, Vivancos A. Measuring the impact of Next Generation Sequencing (NGS) technique implementation in metastatic colorectal cancer (mCRC) drug development program. J Clin Oncol, The 2015 ASCO Annual Meeting 33(15S), 2015. e-Pub 2015.
172. Kristeleit RS, Brown NF, F Hess D, Joerger M, Von Moos R, Rodon J, Hierro C, Childs A, Stathis A, Dimitrijevic S, Stumm M, Herrmann R, Sessa C, Bize V, Hess V, Wicki A. A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results. J Clin Oncol, The 2015 ASCO Annual Meeting 33(15S), 2015. e-Pub 2015.
173. Racca F, Hierro C, Moreno D, Vilaro M, Landolfi S, Vivancos A, Jimenez J, Macarulla T, Capdevila J, Elez E, Argiles G, Sauri T, Cruz C, Azaro A, Castro S, Nuciforo P, Rodon J, Tabernero J, Alsina M. Knocking on molecular alterations in advanced gastric cancer (AGC). J Clin Oncol, Abstracts of the 2015 ASCO Annual Meeting 33(15S), 2015. e-Pub 2015.
174. Sanz-Garcia E, Elez E, Argiles G, Hernandez-Losa J, Vivancos A, Moreno D, Macarulla T, Capdevila J, Alsina M, Sauri T, Hierro C, Azaro A, Zambrano CC, Vilaro M, Jimenez J, Landolfl S, Nuciforo P, Cajal SRY, Rodon J, Tabernero J. Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall d'Hebron Institute of Oncology phase I program cohort. J Clin Oncol, Abstracts of the 2015 ASCO Gastrointestinal Cancers Symposium 33(3S), 2015. e-Pub 2015.
175. Azaro A, Marino D, Garrido-Castro A, Cruz C, Alsina M, Perez J, Dienstmann R, Argiles G, Hierro C, Berzosa M, Adamo B, Tabernero J, Rodon J. PI3K and MEK inhibitor combination toxicities and relative dose intensity: Vail d'Hebron experience. Eur J Cancer, Abstracts of the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 50(6S), 2014. e-Pub 2014.
176. Dienstmann R, Bahleda R, Adamo B, Rodon J, Varga A, Gazzah A, Platero S, Smit H, Perera T, Zhong B, Stuyckens K, Elsayed Y, Takimoto C, Peddareddigari V, Tabernero J, Luo FR, Soria JC. First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors. Cancer Res, AACR Annual Meeting 74(19S), 2014. e-Pub 2014.
177. Garrido-Castro Ana C, Argiles G, Moreno D, Rodriguez-Freixinos, Vilaro M, Macarulla T, Curz Zambrano C, Azaro A, Adamo B, Alsina M, Jimenez J, Nuciforo P, Vivancos A, Meire A, Del Campo JM, Rodon J, Tabernero J, Oaknin A. Molecular profiling in gynecologic cancer and matched targeted therapy: a step toward improving personalized medicine. Clin Oncol, 2014 ASCO Annual Meeting 32(15S), 2014. e-Pub 2014.
178. Fernandez E, ME, Argiles G, Matito J, Mendizabal L, Moreno D, Jimenez J, Hernandez-Losa J, Macarulla T, Capdevila J, Alsina M, Sauri T, Azaro A, Cruz Zambrano C, Landolfi S, Sanz E, Ramon y Cajal S, Nuciforo P, Rodon J, Tabernero J, Vivancos A. Coexisting KRAS and PIK3CA exon 20 mutations as a potential poor-prognosis factor in metastatic colorectal cancer (mCRC). J Clin Oncol, 2014 ASCO Annual Meeting 32(15S), 2014. e-Pub 2014.
179. Rodon J, Dienstmann R, Tabernero J. Genetic analysis in advanced cancer patients: What test for which patient? Matching patient, biomarker and drug. Eur J Cancer 49(2S), 2013. e-Pub 2013.
180. Azaro A, Rodon J, Vansteenkiste J F, Ando Y, Doi T, Mills D, Sarr C, Di Tomaso E, Massacesi, Naumann RW. Hyperglycemia in patients treated with the pan-PI3K inhibitor buparlisib (BKM120): characterization, management, and assessment for pharmacodynamics. Eur J Cancer, Abstracts of the 2013 European Cancer Congress 49(2S):S186, 2013. e-Pub 2013.
181. De Mattos-Arruda L, Oliveira M, Navarro A, Vilaro M, Nuciforo P, Vivancos A, Seoane J, Rodon J, Cores J, Saura C. Molecular profiling of advanced breast cancer patients and benefit obtained from matched targeted therapy in early phase clinical trials. Eur J Cancer, 17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress 2013 49(2S):S418-S418, 2013. e-Pub 2013.
182. Suarez C, Rodon J, Desjardins A, Forsyth P, Gueorguieva I, Cleverly A, Burkholder T, Desaiah D, Lahn M, Wick W. Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming gowth factor-beta (TGF- ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with chemoradiotherapy in newly diagnosed malignant gliomas. J Clin Oncol, 2013 ASCO Annual Meeting 31(15S), 2013. e-Pub 2013.
183. Suarez C, Rodon J, Desjardins A, Forsyth P, Gueorguieva I, Cleverly A, Burkholder T, Desaiah D, Lahn M, Wick W. Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming gowth factor-beta (TGF- ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with chemoradiotherapy in newly diagnosed malignant gliomas. J Clin Oncol, 2013 ASCO Annual Meeting 31(15S), 2013. e-Pub 2013.
184. Amakye D, Robinson D, Rose K, Y-J C, Sharp T, Ando Y, Geoerger B, Doz F, Ashley D, Hargrave D, Casanova M, Tawbi H, Heath J, Bouffet E, Brandes AA, Chisholm J, Rodon J, Thomas A, Mita A, MacDonald T, Kieran M. Development of a five-gene hedgehog signature as a patient preselection tool for hedgehog pathway-targeted therapy in medulloblastoma. Neuro-Oncology, Abstracts of the 2nd Annual Pediatric Neuro-Oncology Basic and Translational Research Conference 15(1S), 2013. e-Pub 2013.
185. Nuciforo P, Prudkin L, Aura C, Jimenez J, Peiro P, Martinez P, Vivancos A, Moreno D, Rodon J. Incorporation of PTEN Status Determination in Routine Molecular Prescreening for Targeted Therapies. Modern Pathology, 2014, 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 27(2S):466A-466A, 2013. e-Pub 2013.
186. Soria JC, Tsimberidou AM, Kurzrock R, Tabernero J, Rodon J, Berger R, Onn A, Batist G, Bresson C, Lazar V. Winther: a study to select rational therapeutics based on the analysis of tumor and matched normal tissue biopsies in subjects with advanced malignancies. Ann Oncol 24(1S), 2013. e-Pub 2013.
187. Tabernero J, Dienstmann R, Macarulla T, Saura C, Argiles G, Alsina M, Cruz C, Brana I, Cortes J, Rodon J. 2 Agents Targeting the mTOR-PI3K-Akt Pathway. Eur J Cancer, Abstracts of the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 48(6S):3, 2012. e-Pub 2012.
188. Delgado Colston A, Banos M, Soria M, Azaro A, Dienstmann R, Argiles G, Cruz C, Capdeville J, Tabernero J, Rodon J. QTc Intervals as Inclusion/exclusion Criteria in Phase I Trial with Anticancer Agents: Vall d'Hebron Experience. Eur J Cancer, Abstracts of the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 48(6S):189-190, 2012. e-Pub 2012.
189. Maira M, Schnell C, Lollini P, Chouaid C, Schmid P, Nanni P, Lam D, Di Tomaso E, Massacesi C, Rodon J. Preclinical and preliminary clinical activity of NVP-BKM120, an oral PAN-CLASS I PI3K inhibitor, in the brain. Ann Oncol, Abstracts of the 37th ESMO Congress 23(9S), 2012. e-Pub 2012.
190. Rodon J, Bendell J, Razak ARA, De Jonge MJA, Eskens F, Di Tomaso E, Sternberg DW, Wang L, Sarr C, Baselga J. A Phase I dose escalation and expansion trial of BKM120, an oral PAN-PI3K inhibitor, in patients with advanced solid tumors: analysis of pharmacodynamic biomarker data. Ann Oncol, Abstracts of the 37th Congress of the European-Society-for-Medical-Oncology 23(9S), 2012. e-Pub 2012.
191. Serra V, Rodon J, Aura CM, Vivancos A, Stemke-Hale K, Hibshoosh H, Wang Y, Ramon y Cajal S, Tabernero J, Baselga J. Evaluation of PTEN and PIK3CA status in breast cancer for patient selection. Ann Oncol, Abstracts of the 37th ESMO Congress 23(9S), 2012. e-Pub 2012.
192. Navarro A, Oliveira M, De Mattos-Arruda L, Sánchez-Ollé G, Bellet M, Balmaña J, Gómez-Pardo P, Perez-Garcia JM, Muñoz-Couselo E, Vidal M, Ortega V, Dienstmann R, Aura C, Hernandez-Losa J, Rodon J, Cajal SRY, Baselga J, Tabernero J, Cortes J, Saura C. Prognostic significance of PI3K pathway (PI3Kp) dysregulation in metastatic breast cancer (MBC) patients (pts). J Clin Oncol, 2012 ASCO Annual Meeting 30(15S), 2012. e-Pub 2012.
193. Oliveira M, Navarro A, De Mattos-Arruda L, Sánchez-Ollé G, Bellet M, Balmaña J, Gómez-Pardo P, Perez-Garcia JM, Muñoz-Couselo E, Vidal M, Ortega V, Dienstmann R, Aura C, Prudkin L, Vivancos A, Rodon J, Baselga J, Tabernero J, Cortes J, Saura C. PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts). J Clin Oncol, 2012 ASCO Annual Meeting 30(15S), 2012. e-Pub 2012.
194. Krop IE, Saura C, Rodon J, Becerra C, Britten CD, Isakoff SJ, Demanse D, Hackl W, Quadt C, Silva AP, Burris HA, Abu-Khalaf MM, Baselga J. A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer. J Clin Oncol, 2012 ASCO Annual Meeting 30(15S), 2012. e-Pub 2012.
195. Calvo E, Benhadji K, Azaro A, Duran I, Argiles G, Boni V, Ohnmacht U, Wallin J, Bumgardner WM, Rodon J. First-in-human phase I study of LY2780301, an oral P70S6K/AKT inhibitor, in patients with refractory solid tumors. J Clin Oncol, 2012 ASCO Annual Meeting 30(15S), 2012. e-Pub 2012.
196. Azaro A, Baselga J, Sepúlveda JM, Seoane J, Rodon J, Brana I, Gueorguieva I, Cleverly A, Lahn MMF, Pillay S, Paz-Ares L, Holdhoff M, O'Neill Blakeley J, Carducci MA. The oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: The first human dose study. J Clin Oncol, 2012 ASCO Annual Meeting 30(15S), 2012. e-Pub 2012.
197. Dienstmann R, Sanchez-Olle G, Serpico D, Rodon J, Saura C, Macarulla T, Fernandez MEE, Alsina M, Perez-Garcia JM, Capdevila J, Argiles G, Brana I, Cruz C, Azaro A, Moreno-Fernandez D, Aura C, Hernandez-Losa J, Vivancos A, Cajal SRY, Tabernero J. Molecular profiling of patients (pts) with colorectal cancer (CRC) and matched targeted therapy (MTA) in phase I clinical trials. J Clin Oncol, 2012 ASCO Annual Meeting 30(15S), 2012. e-Pub 2012.
198. Serra V, Rodon J, Aura C, Prudkin L, Aura C, Vivancos A, Ibrahim YH, Maurer M, Hibshoosh H, Stemke-Hale K, Jimenez J, Wang Y, Peg V, Hernandez J, Ramon y Cajal S, Dienstmann R, Saura C, Sanchez G, Tabernero J, Parsons R, Mills G, Baselga J. Evaluation of PTEN and PIK3Ca status in breast cancer for patient selection: cross-validation between institutions. Cancer Res, Proceedings of the 103rd AACR Annual Meeting 72(8S), 2012. e-Pub 2012.
199. Rodon J, Bendell JC, Abdul Razak AR, Homji N, Trandafir L, Quadt C, Graña-Suárez B, Siu LL, Di Tomaso E, Demanse D, Massacesi C, Hirawat S, Burris III HA, Baselga J. Safety Profile and Clinical Activity of Single-Agent BKM120, a Pan-Class I PI3K Inhibitor, for the Treatment of Patients with Metastatic Breast Carcinoma. Cancer Res, CTRC-AACR SABCS Meeting 71, 2011. e-Pub 2011.
200. De Mattos-Arruda L, Oliveira M, Sánchez-Ollé G, Moreno-Fernandez D, Graña B, Cortes J, Bellet M, Di Cosimo S, Gomez Pardo P, Rodon J, Perez-Garcia JM, Vidal M, Muñoz-Couselo E, Hernandez-Losa J, Vivancos A, Prudkin L, Aura C, Baselga J, Tabernero J, Saura C. Evaluation of overall survival (OS) in patients (pts) with metastatic breast cancer (MBC) according to phosphathidylinositol-3-kinase (PI3K) pathway status. J Clin Oncol, 2011 ASCO Annual Meeting 29(15S), 2011. e-Pub 2011.
201. Rodon J, Baselga J, Calvo E, Seoane J, Brana I, Sicart E, Gueorguieva I, Cleverly A, Lahn MMF, Pillay S, Holdhoff M, Blakeley JO, Carducci MA. First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma. J Clin Oncol, 2011 ASCO Annual Meeting 29(15S), 2011. e-Pub 2011.
202. Bottino D, Tabernero J, Burris HA, Britten C, Chen LC, Bendell JC, Chiparus O, Duval V, Di Tomaso E, Sarr C, Hackl W, Baselga J, Rodon J. Clinical pharmacokinetic-pharmacodynamic (PK/PD) modeling study of the novel dual PI3K/mTOR inhibitor BEZ235. J Clin Oncol, 2011 ASCO Annual Meeting 29(15S), 2011. e-Pub 2011.
203. Grana B, Burris HA, Rodon J, Abdul Razak AR, De Jonge MJ, Eskens F, Siu LL, Ru QC, Homji NF, Demanse D, Di Tomaso E, JGCE C, Quadt C, Baselga J, Bendell JC. Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy. J Clin Oncol, 2011 ASCO Annual Meeting 29(15S), 2011. e-Pub 2011.
204. Suarez C, Gallardo E, Rodon J, Guix M, Bonfill T, Pons F, Beltran M, Moya I, Galtes S, Albanell J, Carles J, Bellmunt J. Phase I study of sunitinib in combination with gemcitabine/capecitabine for the first-line treatment of metastatic or unresectable renal cell carcinoma. J Clin Oncol, 2011 ASCO Annual Meeting 29(15S), 2011. e-Pub 2011.
205. Oliveira M, De Mattos-Arruda L, Sánchez-Ollé G, Graña B, Cortes J, Perez-Garcia JM, Muñoz-Consuelo E, Vidal M, Bellet M, Di Cosimo S, Gomez Pardo P, Rodon J, Hernandez-Losa J, Vivancos A, Prudkin L, Aura C, Serra V, Baselga J, Tabernero J, Saura C. Prognostic implications of phosphatidylinositol 3-kinase (PI3K) pathway alterations in metastatic triple-negative breast cancer (mTNBC). J Clin Oncol, 2011 ASCO Annual Meeting 29(15S), 2011. e-Pub 2011.
206. Peyton JD, Rodon J, Burris H, Britten C, Chen LC, Tabernero J, Duval V, Rouyrre N, Silva AP, Quadt C, Baselga J. A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors. J Clin Oncol, 2011 ASCO Annual Meeting 29(15S), 2011. e-Pub 2011.
207. Rodon J, Infante J, Burris H, Tabernero J, Ranson MR, Rouyrre N, Duval V, Silva A, Hackl W, Baselga J. A Dose-Escalation Study with a Special Drug Delivery System (SDS) of BEZ235, a Novel Dual PI3K/mTOR Inhibitor, in Patients with Metastatic/Advanced Solid Tumors. Cancer Res, SABCS Meeting 70(24S), 2010. e-Pub 2010.
208. Rodon J, Baselga J, Tawbi H, Shou Y, Dummer R, Feng W, Mahalingam D, Thomas A, Amakye D, Mita A. LDE225, a smoothened (SMO) antagonist: phase I safety and pharmacologic results in patients with advanced tumours. Ann Oncol, Abstract Book of the 35th ESMO Congress Milan 21(8S), 2010. e-Pub 2010.
209. Mahalingam D, Beeram M, Rodon J, Sankhala KK, Mita AC, Benjamin D, Michalek J, Tolcher AW, Wright JJ, Sarantopoulos J. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab (B) in combination with sorafenib (S) in patients (pts) with advanced malignant melanoma. J Clin Oncol, 2010 ASCO Annual Meeting 28(15S), 2010. e-Pub 2010.
210. Edelman G, Bedell C, Shapiro G, Pandya SS, Kwak EL, Scheffold C, Nguyen LT, Laird A, Baselga J, Rodon J. A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol, 2010 ASCO Annual Meeting 28(15S), 2010. e-Pub 2010.
211. Rodon J, Baselga J, Tawbi HA, Shou Y, Granvil C, Dey J, Mita MM, Thomas AL, Amakye DD, Mita AC. A phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors. J Clin Oncol, 2010 ASCO Annual Meeting 28(15S), 2010. e-Pub 2010.
212. Baselga J, De Jonge MJ, Rodon J, Burris III HA, Birle DC, De Buck SS, Demanse D, Ru QC, Goldbrunner M, Bendell JC. A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol, 2010 ASCO Annual Meeting 28(15S), 2010. e-Pub 2010.
213. Burris H, Rodon J, Sharma S, Herbst RS, Tabernero J, Infante JR, Silva A, Demanse D, Hackl W, Baselga J. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. J Clin Oncol, 2010 ASCO Annual Meeting 28(15), 2010. e-Pub 2010.
214. Olmos D, Morales R, Barriuso J, Suárez C, Rodon J, Brunetto A, Baselga J, Sala G, Kaye S, Tabernero J. Prognostic factors of survival in patients in Phase I trials. XII Spanish Society of Medical Oncology Meeting, 2009. e-Pub 2009.
215. Shapiro G, Kwak E, Baselga J, Rodon J, Scheffold C, Laird AD, Bedell C, Edelman G. Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors. J Clin Oncol, 2009 ASCO Annual Meeting 27(15S), 2009. e-Pub 2009.
216. Rothenberg ML, Tolcher AW, Sarantopoulos J, Rodon J, Friberg G, Deng H, McCaffery I, Hwang Y, Puzanov I. AMG 479 monotherapy to treat patients with advanced GI carcinoid tumors: A subset analysis from the first-in-human study. ASCO 2009 Gastrointestinal Cancers Symposium, 2009. e-Pub 2009.
217. Sankhala KK, Takimoto CH, Mita AC, Xiong H, Rodon J, Adinin R, Burns K, Toko T, Arakawa K, Kopetz S. Two phase I, pharmacokinetic (PK) and pharmacodynamic (PD) studies of TAS-109, a novel nucleoside analogue with 14 days and 7 days continuous infusion (CI) schedules. J Clin Oncol, 2008 ASCO Annual Meeting 26(15S), 2008. e-Pub 2008.
218. Mahany JJ, Lewis N, Heath EI, LoRusso PM, Mita MM, Rodon J, Tolcher AW, Sherman BM, Bradley CR, Papadopoulos KP. A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors. J Clin Oncol, 2008 ASCO Annual Meeting 26(15S), 2008. e-Pub 2008.
219. Rodon J, Malik G, W-H W, Sankhala K, Wick M, Dancey J, Papadoupolos K. Antitumor effects of sorafenib, bevacizumab and cetuximab as single agents or in combination with an MEK, mTOR or bcl-2 inhibitor, in a SNU-398 human hepatocellular tumor xenograft model. Cancer Res, AACR Annual Meeting 2008 68, 2008. e-Pub 2008.
220. Rodon J, Andrew H, Hammoudeh R, Takimoto C, Tolcher A. Descriptive analysis of the use of biomarkers in the early development of targeted therapies. Mol Cancer Ther, Procceedings from the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. Experience in San Antonio phase I program 6(B69), 2007. e-Pub 2007.
221. Stein M, Yazji S, Rodon J, Miles D, O’Rourke P, Papadopoulos K, Mita AC. A phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of XL820 administered orally daily (QD) or twice daily (BID) to patients (pts) with solid malignancies. Mol Cancer Ther, Proceedings from the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 6(C45), 2007. e-Pub 2007.
222. Rodon J, Patnaik A, Stein M, Tolcher AW, Ng C, Dias C, Greig G, Frankel S, Kurzrock R, Rubin E. A phase I study of q3W R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist in patients with advanced solid tumors. Mol Cancer Ther, Proceedings from the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 6(A77), 2007. e-Pub 2007.
223. Lin C, Papadopoulos K, Patnaik A, Sankhala K, Takimoto CH, Rodon J, Julian T, Brown BD, Tolcher AW. Oblimersen can be administered by subcutaneous (SC) and brief intravenous (IV) infusion: Clinical pharmacokinetics and pharmacodynamics (PK/PD) in patients with advanced cancer. J Clin Oncol, 2007 ASCO Annual Meeting 25(18S), 2007. e-Pub 2007.
224. Rodon J, Patnaik A, Stein M, Tolcher A, Ng C, Dias C, Kurman M, Greig G, Kurzrock R, Rubin E. A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer. J Clin Oncol, 2007 ASCO Annual Meeting 25(18S), 2007. e-Pub 2007.
225. Tolcher AW, Rothenberg ML, Rodon J, Delbeke D, Patnaik A, Nguyen L, Young F, Hwang Y, Haqq C, Puzanov I. A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J Clin Oncol, 2007 ASCO Annual Meeting 25(18S), 2007. e-Pub 2007.
226. Rodon J, Beeram M, de Bono JS, Patnaik A, Mita A, O'Rourke P, Bruno S, Papadopoulos K, Takimoto C, Tolcher A. Impressive anti-tumor activity of combined erbB1 and erbB2 blockade with OSI-774 (erlotinib; E) and trastuzumab (T) in combination with weekly paclitaxel (P) in patients (pts) with trastuzumab refractory breast cancer in a phase I pharmacokinetics (PK) study. 29th San Antonio Breast Cancer Symposium, San Antonio, Texas, Breast Cancer Research and Treatment 100 (suppl 1)(S68-S69), 2006. e-Pub 2006.
227. Burris HA, Krop IE, Modi S, Rodon J, Lutzker SG, Holden SN, Rabbee N, Tibbitts J, Sliwkowski MX, Beeram M. A Phase I Study of a First-in-Class HER2 Antibody-Drug Conjugate in Patients with HER2-Overexpressing Metastatic Breast Cancer. 29th San Antonio Breast Cancer Symposium, San Antonio, Texas, Breast Cancer Research and Treatment 100 (suppl 1)(S104-S104), 2006. e-Pub 2006.
228. Kruzelock R, W-H W, Courage J, Short W, Dominguez C, Rodon J, Tolcher A, Takimoto C. Development of a 300,000 Base Pair Custom Sequencing Microarray for Biomarker Discovery and Anticancer Drug Development. Eur J Cancer, EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 4(2):144-145, 2006. e-Pub 2006.
229. Papadopoulos K, Rodon J, Mita A, O’Rourke P, Patnaik A, Rubin E, Tolcher A, Stein M. A phase I dose-escalation study of the safety and pharmacokinetics of a novel spectrum selective kinase inhibitor XL820, administered orally to patients with solid tumors. Eur J Cancer 4(12):33, 2006. e-Pub 2006.
230. Rodon J, Till E, Patnaik A, Takimoto C, Beeram M, Williams D, Bowen C, Hodge J, Dar M, Tolcher A. Phase I study of ispinesib (SB-715992) in combination with capecitabine in patients with advanced solid tumors. Eur J Cancer Supplements, EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 4(12):193, 2006. e-Pub 2006.
231. Rodon J, Hsu A, Takimoto C, Geller R, Tolcher A. Development of biomarkers in phase I trials of targeted therapies: the reality of the clinical research forefront. Clin Cancer Res, Proceedings of the First AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development 12(B74), 2006. e-Pub 2006.
232. Mita MM, Mita AC, Ricart A, Rodon J, Till E, Okereke C, Desai P, Zang E, Rowinsky EK, Takimoto C. Phase I study of an anti-angiogenic agent with a novel mechanism of action E7820: Safety, pharmacokinetics (PK) and pharmacodynamic (PD) studies in patients (pts) with solid tumors. J Clin Oncol, 2006 ASCO Annual Meeting 24(18S), 2006. e-Pub 2006.
233. Rodon J, Garcia M, Perez J, Navarro M, Pareja L, Germà-Lluc JR. Adjuvant treatment in Stage III colon cancer: Comparison of patients recruited into trials and those treated outside a clinical trial: analysis of recruitment, trial effect and inclusion of elderly patients. J Clin Oncol, ASCO Annual Meeting Proceedings 23(16S), 2005. e-Pub 2005.
234. Rodon J, Mesía R, Cacicedo J, Gómez J. Feasibility study of an adjuvant protocol with chemo-radiation in Head and Neck Cancer. National Congress of the SEOM (Spanish Society of Clinical Oncology), 2005. e-Pub 2005.
235. Martinez M, Del Rio C, Navarro M, Pareja L, Martinez-Villacampa M, Dotor E, Rodon J, Cambray M. Preoperative chemoradiotherapy for locally advanced resectable rectal cancer. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, 2004. e-Pub 2004.
236. Majem M, Martinez M, Galiana R, Montes A, Cardenal F, Rodon J, Nogues J, Perez FJ, Gomez J, Mesia R. Analysis of 46 patients with nasopharyngeal carcinoma treated with hyperfractionated radiotherapy in a single institution. J Clin Oncol, ASCO Annual Meeting Proceedings 22(14S), 2004. e-Pub 2004.
237. Navarro M, Martinez M, Pareja M, Martinez-Villacampa M, Rodon J. Analysis of 305 patients with advanced colorectal cancer treated with one or more lines of palliative chemotherapy. World Congress on Gastrointestinal Cancer, 2004. e-Pub 2004.
238. Navarro M, Rodon J, Pareja L, Martinez M, Ribas J. Survival impact of a multidisciplinary approach of colorectal cancer in a single institution comprehensive cancer center. World Congress on Gastrointestinal Cancers, 2004. e-Pub 2004.
239. Martinez M, Majem M, Rodon J, Navarro M. Chemo-radiotherapy in locally advanced esophageal carcinoma. World Congress on Gastrointestinal Cancers, 2004. e-Pub 2004.
240. Rodon J, Martinez M, Galan M, Navarro M. Adjuvant chemo-radiation of pancreatic cancer in a realistic setting: results from a comprehensive cancer center in a population based series. World Congress on Gastrointestinal Cancers, 2004. e-Pub 2004.

Book Chapters

1. Batchelor T, Rodon J, Ahluwalia M. Principles of pharmacotherapy. In: Handb Clin Neurol, 149-62, 2016.
2. Rodon J, Azaro A, Torrejon D, Kurzrock R. Combining Targeted Therapies. In: Targeted Therapy in Translational Cancer Research. First, 14-26, 2015.
3. Mulet-Margalef N, Miquel JM, Rodon J. Polymer-drug conjugates. In: Drug Delivery in Oncology, 56-73, 2014.
4. Brana I, De Dosso S, Dienstmann R, Rodon J, Tabernero J, Markman B. Recent Developments in Anticancer Agents Targeting PI3K, AKT and mTORC1/2 95. In: Topics in Anti-Cancer Research. 102, 95-196, 2013.
5. Balmaña J, Rodon J. Converting cancer susceptibility and hereditary genetic alterations in therapeutic opportunities. In: Hereditary Cancer. Spanish Society of Medical Oncology, 277-296, 2010.
6. Rodon J. Hypercalcemia. In: Symptom Control in advanced and terminal cancer. Aran, 305-309, 2004.
7. Rodon J. Inadequate secretion of antidiuretic hormone. In: Symptom Control in advanced and terminal cancer. Aran, 309-313, 2004.

Books (edited and written)

1. Yap TA, Rodon J, Hong D. Phase I Oncology Drug Development. Springer, 2020.
2. Kluwer W. Handbook of Targeted Cancer Therapy 2nd Edition, 2018.